This document is the third edition of a book on lung cancer edited by Jack A. Roth, James D. Cox, and Waun Ki Hong. It contains chapters written by experts on various topics related to lung cancer, including smoking cessation, lung cancer genetics, detection and diagnosis of preneoplastic lung lesions, surgical and non-surgical treatments, targeted therapies, screening and prevention. The book provides a comprehensive overview of the current state of knowledge across the multidisciplinary field of lung cancer research and clinical management.
Pancreatic cystic neoplasm: Definition, Classification, Diagnosis and treatment.Marco Castillo
A brief description of the different pancreatic cystic neoplasms and the pseudocyst, including, eidemiology, classification, risk of malignancy, histology, imaging techniques for diagnosis and treatment.
Small cell lung cancer (SCLC) accounts for 13% of lung cancers and is strongly linked to smoking. SCLC typically presents as a large mass in the mediastinal lymph nodes. It is classified as limited stage, confined to one lung, or extensive stage with distant metastases. Treatment involves chemotherapy with cisplatin and etoposide, and sometimes radiation therapy. For limited stage SCLC, surgery may be an option for early tumors. While initial response rates are high, most patients experience relapse. Prophylactic cranial irradiation can reduce the risk of brain metastases. Even with optimal treatment, the 5-year survival rate remains low at 5-10% for extensive stage and 30-40% for limited stage disease
1) Esophageal cancer is often discovered late and has an overall 5-year prognosis of less than 10%. Even for potentially resectable esophageal cancer, 5-year survival is less than 30%.
2) The most common benign esophageal tumor is leiomyoma, which typically causes dysphagia or hematemesis if large. Malignant esophageal tumors are usually adenocarcinoma or squamous cell carcinoma.
3) Risk factors for squamous cell carcinoma include alcohol, tobacco, HPV infection, radiation exposure, and achalasia. Symptoms include progressive dysphagia and weight loss. Diagnosis involves endoscopy with biopsy. Treatment depends on cancer staging and
This document discusses lung cancer, including its anatomy, staging, diagnostic imaging, and treatment options. It provides details on the lobes of the lungs, lymph node stations, and the importance of lymph node involvement in staging. Imaging techniques like CT, PET, and PET/CT are described. Treatment depends on cancer type and stage, and may involve surgery, chemotherapy, radiation therapy, or a combination. Side effects of radiation treatment are also outlined.
This document provides an overview of the management of hepatocellular carcinoma (HCC). It discusses the epidemiology, risk factors, diagnosis and staging, as well as treatment options for HCC. The major risk factors for HCC include hepatitis B virus, hepatitis C virus, and alcohol. Treatment depends on the stage and includes options such as liver transplantation, resection, ablation, transarterial chemoembolization, and the systemic therapy sorafenib. Prevention through vaccination and treating underlying liver diseases can help reduce cases of HCC.
- A 60 year old smoker presented for a routine physical and was found to have an abnormality on chest x-ray
- The next appropriate test would be a CT scan of the chest with IV contrast to further characterize any lung lesions found on CXR
- A CT-guided biopsy would not be the next test, as further imaging is needed first to identify and stage any potential lung cancer before invasive testing
The best answer is A) CT chest with IV contrast to further evaluate and characterize any lung abnormalities found on CXR before considering an invasive biopsy.
Lung cancer forms in the lungs and can spread to other organs. It is the leading cause of cancer death in the United States, with around 200,000 new cases and 159,000 deaths annually. Smoking is the primary risk factor, causing around 90% of lung cancer cases. The two main types are non-small cell lung cancer and small cell lung cancer, which are diagnosed and treated differently depending on the cancer's stage and size. Research continues on new treatments to improve survival rates.
Pancreatic cystic neoplasm: Definition, Classification, Diagnosis and treatment.Marco Castillo
A brief description of the different pancreatic cystic neoplasms and the pseudocyst, including, eidemiology, classification, risk of malignancy, histology, imaging techniques for diagnosis and treatment.
Small cell lung cancer (SCLC) accounts for 13% of lung cancers and is strongly linked to smoking. SCLC typically presents as a large mass in the mediastinal lymph nodes. It is classified as limited stage, confined to one lung, or extensive stage with distant metastases. Treatment involves chemotherapy with cisplatin and etoposide, and sometimes radiation therapy. For limited stage SCLC, surgery may be an option for early tumors. While initial response rates are high, most patients experience relapse. Prophylactic cranial irradiation can reduce the risk of brain metastases. Even with optimal treatment, the 5-year survival rate remains low at 5-10% for extensive stage and 30-40% for limited stage disease
1) Esophageal cancer is often discovered late and has an overall 5-year prognosis of less than 10%. Even for potentially resectable esophageal cancer, 5-year survival is less than 30%.
2) The most common benign esophageal tumor is leiomyoma, which typically causes dysphagia or hematemesis if large. Malignant esophageal tumors are usually adenocarcinoma or squamous cell carcinoma.
3) Risk factors for squamous cell carcinoma include alcohol, tobacco, HPV infection, radiation exposure, and achalasia. Symptoms include progressive dysphagia and weight loss. Diagnosis involves endoscopy with biopsy. Treatment depends on cancer staging and
This document discusses lung cancer, including its anatomy, staging, diagnostic imaging, and treatment options. It provides details on the lobes of the lungs, lymph node stations, and the importance of lymph node involvement in staging. Imaging techniques like CT, PET, and PET/CT are described. Treatment depends on cancer type and stage, and may involve surgery, chemotherapy, radiation therapy, or a combination. Side effects of radiation treatment are also outlined.
This document provides an overview of the management of hepatocellular carcinoma (HCC). It discusses the epidemiology, risk factors, diagnosis and staging, as well as treatment options for HCC. The major risk factors for HCC include hepatitis B virus, hepatitis C virus, and alcohol. Treatment depends on the stage and includes options such as liver transplantation, resection, ablation, transarterial chemoembolization, and the systemic therapy sorafenib. Prevention through vaccination and treating underlying liver diseases can help reduce cases of HCC.
- A 60 year old smoker presented for a routine physical and was found to have an abnormality on chest x-ray
- The next appropriate test would be a CT scan of the chest with IV contrast to further characterize any lung lesions found on CXR
- A CT-guided biopsy would not be the next test, as further imaging is needed first to identify and stage any potential lung cancer before invasive testing
The best answer is A) CT chest with IV contrast to further evaluate and characterize any lung abnormalities found on CXR before considering an invasive biopsy.
Lung cancer forms in the lungs and can spread to other organs. It is the leading cause of cancer death in the United States, with around 200,000 new cases and 159,000 deaths annually. Smoking is the primary risk factor, causing around 90% of lung cancer cases. The two main types are non-small cell lung cancer and small cell lung cancer, which are diagnosed and treated differently depending on the cancer's stage and size. Research continues on new treatments to improve survival rates.
A common site for advanced colorectal cancer to spread is the liver. In this webinar we will discuss why that happens and some treatment options available for patients facing liver metastases.
Presenting is Dr. Fakih’s whos research focuses on drug development, surveillance and prevention of colorectal cancer. In January 2015, he was appointed as the Interim Chair of Medical Oncology at City of Hope.
Soft tissue sarcomas are rare malignant tumors that can arise in any soft tissue of the body. They are characterized by their genetic alterations and histological grade. Diagnosis is made through biopsy and imaging is used to stage the tumor. Treatment typically involves complete surgical resection with negative margins, along with possible adjuvant radiation and chemotherapy depending on tumor grade and size. Prognosis depends on factors like tumor size, grade, depth, and completeness of resection. Recurrence rates remain high, especially for retroperitoneal and visceral soft tissue sarcomas.
The document discusses the anatomy and divisions of the mediastinum. It is divided into superior, anterior, middle and posterior compartments by imaginary lines. The superior mediastinum contains structures like the thymus, great vessels and nerves. The anterior mediastinum contains the thymus and lymph nodes. The middle mediastinum contains the heart and great vessels. The posterior mediastinum contains the esophagus and descending aorta. Common mediastinal tumors are discussed along with their locations.
This document provides information on lung cancer including:
- Lung cancer is one of the most common cancers worldwide and the leading cause of cancer death.
- Tobacco smoking is the main risk factor, causing over 70% of lung cancer deaths.
- Lung cancers are classified as small cell lung carcinoma and non-small cell lung carcinoma (NSCLC), which includes adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.
- NSCLC is more common and is diagnosed based on histopathological examination and immunohistochemistry (IHC) staining. Targeted therapies exist for mutations in EGFR and ALK genes.
Prostatic cancer is the most commonly diagnosed malignancy in men beyond middle age. The prostate gland is located below the bladder and surrounds the urethra. Cancer usually develops in the peripheral zone and can spread locally or metastasize through the lymphatic system or bloodstream, commonly to bone. Diagnosis involves a PSA test, digital rectal exam, and biopsy. Treatment options depend on stage but may include surgery, radiation, hormone therapy, or active surveillance. Prognosis depends on stage and grade, with early-stage disease having an excellent long-term survival.
Carcinoma of the prostate; Incidence, Epidemiology, Aetiology, Clinical features, Workup, and Management.
by Osman Altohamy, A Fifth year Medical Student, Gezira, Sudan
osmansalahe@icloud.com
osmansalahe@hotmail.com
Metastases are tumor implants discontinuous from the primary tumor. Pulmonary metastases most commonly present as multiple pulmonary nodules and are usually bilateral with a basal predominance. They most often spread to the lungs via the bloodstream. The lungs act as a filter for the blood, allowing cancer cells from primary tumors in many sites like breast, bone, and urogenital organs to become lodged in the lungs. Radiologically, metastases typically appear as rounded nodules but can also cavitate, calcify, or cause consolidations. Diagnosis involves determining the primary site through clinical evaluation, imaging, and biopsy of lesions. Treatment options include chemotherapy, radiation, surgery, and palliative care.
The document provides an overview of the Egyptian HCC Guidelines presented by Mohamed A. Ezzel Arab MD. It summarizes the guidelines on primary, secondary, and tertiary prevention of HCC. It also outlines recommendations for screening, diagnosis, staging, treatment including surgical resection, locoregional therapies, transplantation, and systemic therapies. Post-treatment monitoring guidelines are also presented. The document aims to provide evidence-based guidelines tailored to factors in Egypt based on international guidelines and expert opinion.
- Small cell lung cancer (SCLC) accounts for 10-20% of lung cancers and is strongly linked to smoking. It is an aggressive neuroendocrine tumor that typically recurs after initial treatment.
- SCLC is classified as limited stage (confined to one lung and regional lymph nodes) or extensive stage (has spread widely). Limited stage has a median survival of 16-24 months with chemotherapy and radiation, while extensive stage has a median survival of 6-12 months with chemotherapy alone.
- First-line treatment is platinum-based chemotherapy for both stages. Limited stage also receives chest radiation. Prophylactic cranial irradiation reduces the risk of brain metastases. However, recurrence is common due to S
Lung tumors are commonly fatal malignancies that occur most often in adults aged 40-70 years. The main risk factors are cigarette smoking, air pollution, asbestos exposure, and certain industrial chemicals. The most common types are squamous cell carcinoma, adenocarcinoma, large cell carcinoma, and small cell carcinoma. Clinical presentation depends on whether the tumor is localized, invasive, or metastatic. Imaging techniques like chest X-ray, CT, MRI, PET, and PET-CT are used to characterize tumors and detect spread. Treatment options vary based on tumor type and stage.
Superior vena cava syndrome is caused by obstruction of blood flow through the superior vena cava, which drains blood from the upper half of the body. The most common causes are lung cancer and lymphoma. Symptoms include swelling of the face, neck and arms, cough, difficulty breathing. Diagnosis involves imaging tests and biopsy. Treatment depends on severity and cause, and may include supportive care, stents, chemotherapy, radiation therapy or surgery. Endovascular stents provide rapid symptom relief in many cases.
Basic information for discussion with a healthcare professional is provided here together with some background:
• An enlargement or the presence of tumors in the gland below a man’s bladder that produces fluid for semen ie, the prostate, may suggest benign prostatic hyperplasia (BPH) or prostate cancer
o Almost 8% of new cancer cases worldwide are attributed to this highly curable disease (proportion of patients surviving after 5 years = 98.9%)
o In the USA alone, prostate cancer is the most common non-skin cancer, diagnosed more often in African-American (1 in 5 cases) than white men (1 in 6 cases)
o Prostate cancer is strongly correlated with age, starting at about 50 years old and rising over the ensuing decades
o While debates over under- or over-treatment of prostate cancer continue, it is clear that management of the disease costs the USA an aggregate annual loss in productivity of $3.0 billion
o Moreover, prostate cancer is the third-leading cause of cancer-related deaths in the USA, mainly due to advanced or metastatic disease
The document discusses the management of Wilms' tumor, a type of kidney cancer that typically affects children. It covers the history, epidemiology, pathogenesis, pathology, clinical features, workup, staging, and treatment approaches for Wilms' tumor. Treatment typically involves surgical removal of the tumor, followed by chemotherapy and sometimes radiation therapy, with the goal of eliminating both the primary tumor and any metastases in a multidisciplinary, stage-adapted approach.
Define Structure of Cell
Define cancer
Explain Lung Cancer
Explain Epidemiology or statistics of Lung Cancer
Signs and Symptoms of Lung Cancer
risk factors of Lung cancer
methods used to diagnose lung cancer
treatment given to lung cancer
preventive measures of Lung Cancer
This document discusses treatment options for cancer of the esophagus. It covers staging, endoscopic resection options for early stage cancers, preoperative chemoradiation followed by surgery as standard treatment for locally advanced cancers, and types of surgery and postoperative care. Chemotherapy regimens including cisplatin and fluorouracil provide response rates of 20-30% for metastatic cancers. Overall, the document provides an overview of current guidelines and evidence for endoscopic, surgical, radiation, and chemotherapy approaches to esophageal cancer treatment based on tumor stage.
This document discusses lung cancer including its epidemiology, etiology, classification, clinical manifestations, diagnostic evaluation, staging, and management. Some key points:
- Lung cancer is the leading cause of cancer death in the US, caused primarily by cigarette smoking which is responsible for 80-90% of cases.
- Lung cancers are classified as non-small cell carcinomas (which make up 70-75% of cases), small cell carcinomas, or metastatic lung cancers.
- Symptoms often do not appear until late stages and include cough, hemoptysis, dyspnea, and chest pain. Metastatic cancers can cause additional symptoms.
- Diagnostic tests include chest x
Bladder cancer is the fourth most common cancer in men and seventh most common in women. 90-95% of cases are transitional-cell carcinoma. Standard treatment for superficial bladder cancer is transurethral resection followed by adjuvant intravesical therapy to reduce relapse rates by 30-80%. For invasive bladder cancer, radical cystectomy provides 5-year survival rates ranging from 77% for stage I to 12% for stage IV disease. Combined modality therapy with chemotherapy and radiotherapy can yield 5-year survival rates of 50-69% and organ preservation rates of 38-45% for invasive bladder cancer.
This document discusses the management of non-small cell lung cancer. It outlines the various treatment options depending on the stage of cancer, including surgery for early stages, radiation therapy, chemotherapy, and stereotactic body radiotherapy. It provides details on surgical procedures, radiation techniques, outcomes of stereotactic body radiotherapy, and the use of concurrent chemotherapy and radiation for locally advanced stages.
Lung cancer: a 2014 update with information about immunotherapiesZeena Nackerdien
In 2006, Dana Reeve – actress, activist, and non-smoker – died of lung cancer. In 2009, Valerie Harper – actress and “Dancing with the Stars” contestant – was diagnosed with lung cancer that has since metastasized to the brain. They are the famous faces of a disease that is the leading cause of cancer deaths. Five-year survival rates for lung cancer, the leading cause of cancer deaths, are very low. Please take a look at some of the ASCO 2014 lung cancer updates on my blog: http://norwalk.patch.com/groups/zeena-nackerdiens-blog/p/american-society-of-clinical-oncology-annual-meeting-2014-key-lung-cancer-abstracts.
The document discusses lung cancer, including its causes, risk factors, symptoms, diagnosis, staging, and treatment options. Lung cancer is the leading cause of cancer death in men and women. Key risk factors include smoking and exposure to secondhand smoke, radon, asbestos, and other carcinogens. Common symptoms are cough, shortness of breath, wheezing, and chest pain. Diagnosis involves imaging tests and biopsies. Treatment may involve surgery, chemotherapy, radiation therapy, and other approaches depending on the cancer's stage and type.
A common site for advanced colorectal cancer to spread is the liver. In this webinar we will discuss why that happens and some treatment options available for patients facing liver metastases.
Presenting is Dr. Fakih’s whos research focuses on drug development, surveillance and prevention of colorectal cancer. In January 2015, he was appointed as the Interim Chair of Medical Oncology at City of Hope.
Soft tissue sarcomas are rare malignant tumors that can arise in any soft tissue of the body. They are characterized by their genetic alterations and histological grade. Diagnosis is made through biopsy and imaging is used to stage the tumor. Treatment typically involves complete surgical resection with negative margins, along with possible adjuvant radiation and chemotherapy depending on tumor grade and size. Prognosis depends on factors like tumor size, grade, depth, and completeness of resection. Recurrence rates remain high, especially for retroperitoneal and visceral soft tissue sarcomas.
The document discusses the anatomy and divisions of the mediastinum. It is divided into superior, anterior, middle and posterior compartments by imaginary lines. The superior mediastinum contains structures like the thymus, great vessels and nerves. The anterior mediastinum contains the thymus and lymph nodes. The middle mediastinum contains the heart and great vessels. The posterior mediastinum contains the esophagus and descending aorta. Common mediastinal tumors are discussed along with their locations.
This document provides information on lung cancer including:
- Lung cancer is one of the most common cancers worldwide and the leading cause of cancer death.
- Tobacco smoking is the main risk factor, causing over 70% of lung cancer deaths.
- Lung cancers are classified as small cell lung carcinoma and non-small cell lung carcinoma (NSCLC), which includes adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.
- NSCLC is more common and is diagnosed based on histopathological examination and immunohistochemistry (IHC) staining. Targeted therapies exist for mutations in EGFR and ALK genes.
Prostatic cancer is the most commonly diagnosed malignancy in men beyond middle age. The prostate gland is located below the bladder and surrounds the urethra. Cancer usually develops in the peripheral zone and can spread locally or metastasize through the lymphatic system or bloodstream, commonly to bone. Diagnosis involves a PSA test, digital rectal exam, and biopsy. Treatment options depend on stage but may include surgery, radiation, hormone therapy, or active surveillance. Prognosis depends on stage and grade, with early-stage disease having an excellent long-term survival.
Carcinoma of the prostate; Incidence, Epidemiology, Aetiology, Clinical features, Workup, and Management.
by Osman Altohamy, A Fifth year Medical Student, Gezira, Sudan
osmansalahe@icloud.com
osmansalahe@hotmail.com
Metastases are tumor implants discontinuous from the primary tumor. Pulmonary metastases most commonly present as multiple pulmonary nodules and are usually bilateral with a basal predominance. They most often spread to the lungs via the bloodstream. The lungs act as a filter for the blood, allowing cancer cells from primary tumors in many sites like breast, bone, and urogenital organs to become lodged in the lungs. Radiologically, metastases typically appear as rounded nodules but can also cavitate, calcify, or cause consolidations. Diagnosis involves determining the primary site through clinical evaluation, imaging, and biopsy of lesions. Treatment options include chemotherapy, radiation, surgery, and palliative care.
The document provides an overview of the Egyptian HCC Guidelines presented by Mohamed A. Ezzel Arab MD. It summarizes the guidelines on primary, secondary, and tertiary prevention of HCC. It also outlines recommendations for screening, diagnosis, staging, treatment including surgical resection, locoregional therapies, transplantation, and systemic therapies. Post-treatment monitoring guidelines are also presented. The document aims to provide evidence-based guidelines tailored to factors in Egypt based on international guidelines and expert opinion.
- Small cell lung cancer (SCLC) accounts for 10-20% of lung cancers and is strongly linked to smoking. It is an aggressive neuroendocrine tumor that typically recurs after initial treatment.
- SCLC is classified as limited stage (confined to one lung and regional lymph nodes) or extensive stage (has spread widely). Limited stage has a median survival of 16-24 months with chemotherapy and radiation, while extensive stage has a median survival of 6-12 months with chemotherapy alone.
- First-line treatment is platinum-based chemotherapy for both stages. Limited stage also receives chest radiation. Prophylactic cranial irradiation reduces the risk of brain metastases. However, recurrence is common due to S
Lung tumors are commonly fatal malignancies that occur most often in adults aged 40-70 years. The main risk factors are cigarette smoking, air pollution, asbestos exposure, and certain industrial chemicals. The most common types are squamous cell carcinoma, adenocarcinoma, large cell carcinoma, and small cell carcinoma. Clinical presentation depends on whether the tumor is localized, invasive, or metastatic. Imaging techniques like chest X-ray, CT, MRI, PET, and PET-CT are used to characterize tumors and detect spread. Treatment options vary based on tumor type and stage.
Superior vena cava syndrome is caused by obstruction of blood flow through the superior vena cava, which drains blood from the upper half of the body. The most common causes are lung cancer and lymphoma. Symptoms include swelling of the face, neck and arms, cough, difficulty breathing. Diagnosis involves imaging tests and biopsy. Treatment depends on severity and cause, and may include supportive care, stents, chemotherapy, radiation therapy or surgery. Endovascular stents provide rapid symptom relief in many cases.
Basic information for discussion with a healthcare professional is provided here together with some background:
• An enlargement or the presence of tumors in the gland below a man’s bladder that produces fluid for semen ie, the prostate, may suggest benign prostatic hyperplasia (BPH) or prostate cancer
o Almost 8% of new cancer cases worldwide are attributed to this highly curable disease (proportion of patients surviving after 5 years = 98.9%)
o In the USA alone, prostate cancer is the most common non-skin cancer, diagnosed more often in African-American (1 in 5 cases) than white men (1 in 6 cases)
o Prostate cancer is strongly correlated with age, starting at about 50 years old and rising over the ensuing decades
o While debates over under- or over-treatment of prostate cancer continue, it is clear that management of the disease costs the USA an aggregate annual loss in productivity of $3.0 billion
o Moreover, prostate cancer is the third-leading cause of cancer-related deaths in the USA, mainly due to advanced or metastatic disease
The document discusses the management of Wilms' tumor, a type of kidney cancer that typically affects children. It covers the history, epidemiology, pathogenesis, pathology, clinical features, workup, staging, and treatment approaches for Wilms' tumor. Treatment typically involves surgical removal of the tumor, followed by chemotherapy and sometimes radiation therapy, with the goal of eliminating both the primary tumor and any metastases in a multidisciplinary, stage-adapted approach.
Define Structure of Cell
Define cancer
Explain Lung Cancer
Explain Epidemiology or statistics of Lung Cancer
Signs and Symptoms of Lung Cancer
risk factors of Lung cancer
methods used to diagnose lung cancer
treatment given to lung cancer
preventive measures of Lung Cancer
This document discusses treatment options for cancer of the esophagus. It covers staging, endoscopic resection options for early stage cancers, preoperative chemoradiation followed by surgery as standard treatment for locally advanced cancers, and types of surgery and postoperative care. Chemotherapy regimens including cisplatin and fluorouracil provide response rates of 20-30% for metastatic cancers. Overall, the document provides an overview of current guidelines and evidence for endoscopic, surgical, radiation, and chemotherapy approaches to esophageal cancer treatment based on tumor stage.
This document discusses lung cancer including its epidemiology, etiology, classification, clinical manifestations, diagnostic evaluation, staging, and management. Some key points:
- Lung cancer is the leading cause of cancer death in the US, caused primarily by cigarette smoking which is responsible for 80-90% of cases.
- Lung cancers are classified as non-small cell carcinomas (which make up 70-75% of cases), small cell carcinomas, or metastatic lung cancers.
- Symptoms often do not appear until late stages and include cough, hemoptysis, dyspnea, and chest pain. Metastatic cancers can cause additional symptoms.
- Diagnostic tests include chest x
Bladder cancer is the fourth most common cancer in men and seventh most common in women. 90-95% of cases are transitional-cell carcinoma. Standard treatment for superficial bladder cancer is transurethral resection followed by adjuvant intravesical therapy to reduce relapse rates by 30-80%. For invasive bladder cancer, radical cystectomy provides 5-year survival rates ranging from 77% for stage I to 12% for stage IV disease. Combined modality therapy with chemotherapy and radiotherapy can yield 5-year survival rates of 50-69% and organ preservation rates of 38-45% for invasive bladder cancer.
This document discusses the management of non-small cell lung cancer. It outlines the various treatment options depending on the stage of cancer, including surgery for early stages, radiation therapy, chemotherapy, and stereotactic body radiotherapy. It provides details on surgical procedures, radiation techniques, outcomes of stereotactic body radiotherapy, and the use of concurrent chemotherapy and radiation for locally advanced stages.
Lung cancer: a 2014 update with information about immunotherapiesZeena Nackerdien
In 2006, Dana Reeve – actress, activist, and non-smoker – died of lung cancer. In 2009, Valerie Harper – actress and “Dancing with the Stars” contestant – was diagnosed with lung cancer that has since metastasized to the brain. They are the famous faces of a disease that is the leading cause of cancer deaths. Five-year survival rates for lung cancer, the leading cause of cancer deaths, are very low. Please take a look at some of the ASCO 2014 lung cancer updates on my blog: http://norwalk.patch.com/groups/zeena-nackerdiens-blog/p/american-society-of-clinical-oncology-annual-meeting-2014-key-lung-cancer-abstracts.
The document discusses lung cancer, including its causes, risk factors, symptoms, diagnosis, staging, and treatment options. Lung cancer is the leading cause of cancer death in men and women. Key risk factors include smoking and exposure to secondhand smoke, radon, asbestos, and other carcinogens. Common symptoms are cough, shortness of breath, wheezing, and chest pain. Diagnosis involves imaging tests and biopsies. Treatment may involve surgery, chemotherapy, radiation therapy, and other approaches depending on the cancer's stage and type.
the upcoming 8th edition of TNM staging in lung cancer will be published soon. what we need to know about TNM , how it was developed and why? how we can improve our practice for suspected lung cancer patients
Lung cancer is a malignant tumor in the lungs that causes abnormal cells to grow uncontrollably and destroy healthy lung tissue. It is the leading cause of cancer death, with over 222,000 new cases diagnosed and 157,000 deaths expected in 2010 alone. While some progress has been made in treatment, lung cancer remains difficult to cope with and manage due to the physical and emotional challenges it poses for those diagnosed.
Get the facts on Lung Cancer Symptoms, Treatments, Types, Stages, Signs, etc. Get tips on Lung Cancer. For detail information about lung cancer visit us. - Lung Cancer Symptoms, Signs, Treatment & Causes
Degeneration, necrosis, and pathological pigmentationBruno Mmassy
This document provides an overview of degeneration, necrosis, and pathological pigmentation. It defines degeneration as the deterioration of live cells following injury. Various types of cell injuries are classified, including physical, chemical, biological, nutritional, and genetic injuries. The document also describes different types of degenerative changes based on the accumulation of water, carbohydrates, proteins, and lipids inside and outside cells. Examples of each type are given.
This document discusses lung cancer epidemiology, risk factors, pathology, and smoking cessation. It notes that lung cancer is largely caused by tobacco consumption and was rare before the 20th century. While smoking is the primary risk factor, some people who develop lung cancer have never smoked. The four main histological types are small cell lung cancer, adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Stopping smoking can avoid over 90% of lung cancer risk from tobacco. Occupational exposures like asbestos and radiation also increase lung cancer risk.
Este documento describe el cáncer de mama, incluyendo la incidencia y mortalidad en Colombia, los retos de la detección tardía, y los avances en la mejora de la estadificación, menor invasión quirúrgica y el uso de perfiles genómicos. En particular, se discute el uso del ensayo Oncotype DX de 21 genes para predecir el riesgo de recurrencia en pacientes con cáncer de mama temprano positivo para receptores hormonales.
8th Edition of the TNM Classification for Lung CancerMauricio Lema
The International Association for the Study of Lung Cancer proposed changes to the TNM classification system for lung cancer in its 8th edition:
- The T descriptor was modified so that tumor size increases in 1 cm increments from T1a to T2b rather than combining sizes.
- Exploratory subgrouping was proposed for N descriptors to distinguish single from multiple lymph node metastases in the future.
- The M descriptor was modified to separate M1 into M1a, M1b for single extra-thoracic metastases, and M1c for multiple extra-thoracic metastases.
- The changes aim to provide more detailed staging information to guide therapy decisions for lung cancer patients.
While lung cancer remains a very challenging cancer to treat, new treatments that capitalize on advances in our understanding of cancer. It is likely that a more personalized approach to treatment using biological markers and combinations of therapies will provide better results in the future.
The document provides updates from various departments at the Kimmel Cancer Center. It announces new treatments for prostate cancer including high intensity focused ultrasound. It highlights advances in areas like radiation oncology, integrative medicine, and stem cell research. It recognizes support from donors and announces new rankings for cancer care.
This document provides an introduction to the book "Practical Geriatric Oncology". It discusses how cancer risk increases with age and the number of older cancer patients is rising. It describes how cancer treatment for older patients differs from younger adults due to biological and psychosocial factors. The book comprehensively addresses geriatric oncology topics like assessment, management of solid tumors and hematologic malignancies, pharmacology, surgery, radiation oncology, and supportive care. It serves as core reading for oncologists and other health professionals treating older cancer patients.
This document provides an overview of the book "Image-guided Radiotherapy of Lung Cancer". It discusses how image-guided radiotherapy (IGRT) using techniques like PET/CT, 4D-CT, gated radiotherapy, IMRT and proton radiotherapy have introduced a new era for radiotherapy treatment of lung cancer. The book focuses on these novel IGRT approaches and provides recommendations on dose/fractionation, target volume delineation, treatment techniques and normal tissue tolerances. It aims to establish disease stage-specific guidelines to help radiation oncologists incorporate these advanced techniques into clinical practice for improved patient outcomes.
The University of Virginia Department of Medicine is hosting the 38th Annual Recent Advances in Clinical Medicine Conference from October 26-28, 2011 at the Omni Charlottesville Hotel. The conference will feature lectures on current issues in both outpatient and inpatient care, as well as interdisciplinary sessions on topics such as sleep disorders, joint replacement, and caring for pregnant patients. Attendees will have opportunities to ask questions and discuss cases with speakers. The conference aims to provide practical information that physicians can apply in their practices. It is designed for generalists but also specialists staying updated in their fields.
This chapter discusses the anatomy and histology of the anus. There are several ways to define the boundaries of the anal canal, including anatomically from the dentate line to the anal verge, pathologically as the area between the upper and lower borders of the anal sphincter complex, and surgically as the area between the pelvic floor and anoderm. The anal canal has both squamous and columnar epithelial cells and is innervated by sacral nerves S2-S4. Understanding the anatomy of the anus is important for appropriately staging and treating anal cancer.
Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric CancersLAB IDEA
This chapter discusses tumor markers for liver cancer. Liver cancer, or hepatocellular carcinoma, is a major cause of cancer death worldwide. Early detection is important for effective treatment but many cases are asymptomatic and detected late. The guidelines evaluate tumor markers like alpha-fetoprotein for surveillance of high-risk patients and diagnosis of liver cancer, noting their limitations. Recommendations are provided on the appropriate use of tumor markers in conjunction with imaging for managing liver cancer.
The document summarizes an article from The LANCET Oncology journal about the epidemiology of breast cancer. It includes details about the journal such as its impact factor and indexing. The summary highlights that breast cancer risk is associated with factors that increase estrogen exposure like early menarche and late menopause. Childbearing and breastfeeding may reduce risk. While only a minority of cases are linked to gene mutations, changes to modifiable risk factors like obesity and alcohol consumption could lower breast cancer incidence. The conclusion states that identifying new lifestyle risk factors and chemoprevention trials may further progress in battling breast cancer.
The document describes the approach taken by one institution, Mayo Clinic, to implement individualized medicine into clinical practice through a standalone Individualized Medicine (IM) Clinic. The IM Clinic was designed to overcome barriers to translating genomic medicine into routine patient care. Initial services offered by the IM Clinic included whole exome sequencing for patients with undiagnosed genetic conditions (diagnostic odyssey) and tumor sequencing for cancer patients who have failed standard therapies. The IM Clinic utilizes a multidisciplinary team approach and coordinates various components including genomic counseling, sample collection, sequencing, data analysis, expert review boards, and communication of results to patients. The goals are to improve patient outcomes by enabling more targeted and personalized care approaches.
This document provides information about the fifth edition of the textbook "Cancer of the Head and Neck" including contributors and editors. The textbook is edited by Jeffrey N. Myers, Ehab Y. N. Hanna, and Eugene N. Myers from The University of Texas MD Anderson Cancer Center and provides information on head and neck cancer for medical professionals.
This document lists 20 honored guests who have provided comments and perspectives on published articles related to thoracic oncology. The honored guests include physicians, researchers, and professors from institutions around the world. They have written commentaries on recent clinical trials and studies covering a range of topics within thoracic oncology, including treatments for lung cancer, screening methods, management of side effects, and surgical outcomes. The document provides the names and academic affiliations of each guest contributor and identifies the article each comment is in response to.
This document provides information about the second edition of the textbook "Operative Otolaryngology: Head and Neck Surgery". It lists the editor, Eugene N. Myers, MD, and associate editors from the University of Pittsburgh School of Medicine. It also lists over 100 contributors from various medical departments who authored different chapters in the textbook. The summary provides publishing information including the publisher, copyright details, and international standard book numbers.
Current diagnosis-and-therapy-for-head-and-neck-malBurhan Khan
This article discusses the role of genomic instability in the pathogenesis of squamous cell carcinoma of the head and neck (HNSCC). Genomic instability results in the natural selection of a genomically heterogeneous tumor mass that threatens the organism. Multiple genetic alterations are required for cells to become cancerous, and genomic instability provides an enabling mechanism for tumors to evolve. Understanding genomic instability may help explain the genetic heterogeneity seen in HNSCC tumors and identify new therapeutic targets.
MWEBAZA VICTOR - Nuclear Cardiology The Basics-How To Set Up And Maintain A ...Dr. MWEBAZA VICTOR
This document provides an overview of how to establish and maintain a nuclear cardiology laboratory. It discusses the necessary equipment, staff qualifications, patient preparation, stress testing protocols, imaging acquisition and processing parameters, image analysis and display, reporting, quality assurance, and laboratory accreditation. The goal is to offer practical guidance to cardiologists and nuclear medicine physicians on setting up and running a high-quality outpatient nuclear cardiology facility.
Walter F. Boron, Emile L. Boulpaep - Medical Physiology (2017, Elsevier) - li...RicardoPessoa40
This document provides information about the third edition of the textbook "Medical Physiology" edited by Walter F. Boron and Emile L. Boulpaep. It lists the editors and over 30 contributors to the textbook. The preface discusses updates that have been made to the third edition, including revisions to many chapters to reflect new molecular insights and physiological concepts. Over 190 tables and figures were updated or added, along with an increase in supplemental online notes. The editors aim to integrate concepts from molecular to human physiology and place physiology in a clinical context.
Simon Cooper received his Ph.D. in Radiation/Oncology and has since focused his research career on translating scientific findings into clinical applications while emphasizing patient care. He has authored multiple peer-reviewed articles in collaboration with clinicians and currently leads pre-clinical studies at Mayo Clinic Florida identifying potential new cancer therapies. Cooper aims to continue interacting with clinical researchers to advance innovative patient care.
This document summarizes the implications of COVID-19 for preventing and treating thrombotic complications. It was endorsed by several thrombosis societies and signed by over 60 experts. The key points are:
1) COVID-19 infection is associated with a prothrombotic state and increased risk of thrombotic complications including pulmonary embolism, deep vein thrombosis, ischemic strokes and arterial thromboses.
2) Clinicians should consider prophylactic anticoagulation for hospitalized COVID-19 patients, especially those with elevated D-dimer or inflammatory markers or who are immobilized.
3) Patients with confirmed VTE or arterial events should receive full anticoagulation treatment. Long-term
Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics ( PDFDrive...InsSilva801685
This document provides a table of contents for the book "Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics". The table of contents lists 50 chapters organized into 6 parts that cover topics such as principles of laboratory medicine, analytical techniques and instrumentation, analytes, pathophysiology, molecular diagnostics, and reference information.
Mohammad Rahman is a senior research associate at Ohio State University studying cancer metastasis. He has a PhD in cancer biology from Shimane Medical University in Japan and has held several postdoctoral research positions. His research focuses on how exosomes secreted by cancer cells drive metastasis by inducing epithelial to mesenchymal transition in other cells. He recently discovered that lung cancer cell exosomes can induce EMT in recipient cells, which may be important for establishing the tumor microenvironment and cancer spread. The goal of his current research proposal is to investigate the mechanisms by which cancer-derived exosomal contents drive metastasis.
Mohammad Rahman is a senior research associate at Ohio State University studying cancer metastasis. He has a PhD in cancer biology from Shimane Medical University in Japan and has held several postdoctoral research positions. His research focuses on how exosomes secreted by cancer cells drive metastasis by inducing epithelial to mesenchymal transition in other cells. He recently discovered that lung cancer cell exosomes can induce EMT in recipient cells, which may be important for establishing the tumor microenvironment and cancer spread. The goal of his current research proposal is to investigate the mechanisms by which cancer-derived exosomal contents drive metastasis.
Dokumen tersebut memberikan informasi tentang sistem pertanian tradisional Aceh, termasuk cara meningkatkan hasil pertanian dengan biaya rendah, waktu penanaman yang tepat berdasarkan ilmu falak, dan cara-cara alami untuk mencegah hama tanaman seperti menggunakan jangkrik, daun pandan wangi, dan semut merah. Dokumen ini juga menjelaskan tentang pengolahan tanah secara alami dengan pupuk kandang dan abu bakar.
The document discusses peripheral vascular disease (PVD) and venous thromboembolism (VTE). PVD is underdiagnosed and involves atherosclerosis in arteries outside the heart and brain. Common symptoms include leg pain with walking. VTE has a high prevalence in hospitalized patients, especially those with reduced mobility, and often goes undiagnosed. Ultrasound is useful for diagnosing PVD and Doppler criteria can estimate stenosis. Low molecular weight heparin reduces the risk of VTE compared to unfractionated heparin in heart failure patients.
Proses penuaan manusia ditandai dengan penurunan fungsi hampir seluruh sistem tubuh, meningkatkan kerentanan terhadap penyakit, dan menyebabkan perubahan fisik, psikologis, dan sosial. Proses ini berimplikasi pada berbagai masalah kesehatan seperti penyakit degeneratif dan gangguan fungsional yang memerlukan pendekatan klinis khusus untuk pasien lanjut usia.
Dokumen tersebut membahas tentang penatalaksanaan hipertensi pada preeklampsia. Preeklampsia merupakan komplikasi kehamilan yang berbahaya yang ditandai dengan hipertensi dan proteinuria dan dapat menyebabkan berbagai komplikasi berat bagi ibu dan janin. Patogenesis preeklampsia terkait erat dengan plasenta, di mana terjadinya remodelling vaskuler plasenta yang tidak sempurna menyebabkan hipoperfusi plasenta dan gang
Dokumen tersebut membahas tentang infeksi saluran kemih yang komplikasi (cISK), termasuk definisi, karakteristik, gejala klinis, diagnosa, dan penanganannya. cISK dapat terjadi karena berbagai faktor seperti kelainan anatomi dan fungsi saluran kemih, gangguan ginjal, diabetes, dan imunosupresi. Diagnosa didasarkan pada hasil urinalisis dan kultur bakteri. Pengobatan berfokus pada pemberian antibiotik yang t
1. Nefropati radiokontras merupakan komplikasi umum setelah pemberian radiokontras yang dapat menyebabkan gangguan fungsi ginjal akut.
2. Faktor risiko utama nefropati radiokontras adalah gangguan fungsi ginjal preeksisting, diabetes melitus, volume radiokontras besar, dan administrasi intraarterial.
3. Pencegahan meliputi seleksi pasien berisiko rendah, pemberian volume cairan intravena, dan penggunaan radiokontras den
DEMAM BERDARAH DENGUE Diagnosa dan PenatalaksanaanMulkan Fadhli
The document provides a curriculum vitae for Kurnia F. Jamil which includes his personal details, education history, positions held, additional trainings, and areas of specialization. It also includes a short paper on dengue fever diagnosis and management, describing the virus, pathogenesis, clinical manifestations, diagnostic criteria, differential diagnosis, and treatment approach.
Dokumen ini membahas tentang modulasi digital, yaitu proses penyampaian sinyal pesan digital ke dalam sinyal lain yang dapat ditransmisikan. Terdapat beberapa jenis modulasi digital seperti ASK, FSK, dan PSK yang memanfaatkan amplitudo, frekuensi, dan fasa untuk mewakili bit digital. Modulasi digital memiliki kelebihan seperti daya tahan terhadap noise dibandingkan sistem analog.
The document discusses the immune system and immunoparasitology. It describes the components of the immune system, including specific and nonspecific immunity. It discusses the organs and tissues involved, such as the thymus and bone marrow. It also describes the different immune cells like T cells, B cells, macrophages, and their roles. Furthermore, it discusses cytokines and mediators involved in immune responses and mechanisms by which parasites evade the immune system.
Teks memberikan informasi mengenai ascariasis, penyakit parasit yang disebabkan oleh cacing Ascaris lumbricoides. Cacing ini banyak ditemukan di daerah tropis dengan sanitasi yang buruk. Gejalanya bervariasi dari tidak bergejala hingga menyebabkan gangguan pertumbuhan dan malnutrisi pada infeksi berat, terutama pada anak-anak. Diagnosis didasarkan pada temuan telur cacing pada tinja, sedangkan pengobatannya menggunak
A Strategic Approach: GenAI in EducationPeter Windle
Artificial Intelligence (AI) technologies such as Generative AI, Image Generators and Large Language Models have had a dramatic impact on teaching, learning and assessment over the past 18 months. The most immediate threat AI posed was to Academic Integrity with Higher Education Institutes (HEIs) focusing their efforts on combating the use of GenAI in assessment. Guidelines were developed for staff and students, policies put in place too. Innovative educators have forged paths in the use of Generative AI for teaching, learning and assessments leading to pockets of transformation springing up across HEIs, often with little or no top-down guidance, support or direction.
This Gasta posits a strategic approach to integrating AI into HEIs to prepare staff, students and the curriculum for an evolving world and workplace. We will highlight the advantages of working with these technologies beyond the realm of teaching, learning and assessment by considering prompt engineering skills, industry impact, curriculum changes, and the need for staff upskilling. In contrast, not engaging strategically with Generative AI poses risks, including falling behind peers, missed opportunities and failing to ensure our graduates remain employable. The rapid evolution of AI technologies necessitates a proactive and strategic approach if we are to remain relevant.
How to Add Chatter in the odoo 17 ERP ModuleCeline George
In Odoo, the chatter is like a chat tool that helps you work together on records. You can leave notes and track things, making it easier to talk with your team and partners. Inside chatter, all communication history, activity, and changes will be displayed.
it describes the bony anatomy including the femoral head , acetabulum, labrum . also discusses the capsule , ligaments . muscle that act on the hip joint and the range of motion are outlined. factors affecting hip joint stability and weight transmission through the joint are summarized.
MATATAG CURRICULUM: ASSESSING THE READINESS OF ELEM. PUBLIC SCHOOL TEACHERS I...NelTorrente
In this research, it concludes that while the readiness of teachers in Caloocan City to implement the MATATAG Curriculum is generally positive, targeted efforts in professional development, resource distribution, support networks, and comprehensive preparation can address the existing gaps and ensure successful curriculum implementation.
This presentation was provided by Steph Pollock of The American Psychological Association’s Journals Program, and Damita Snow, of The American Society of Civil Engineers (ASCE), for the initial session of NISO's 2024 Training Series "DEIA in the Scholarly Landscape." Session One: 'Setting Expectations: a DEIA Primer,' was held June 6, 2024.
Strategies for Effective Upskilling is a presentation by Chinwendu Peace in a Your Skill Boost Masterclass organisation by the Excellence Foundation for South Sudan on 08th and 09th June 2024 from 1 PM to 3 PM on each day.
This presentation includes basic of PCOS their pathology and treatment and also Ayurveda correlation of PCOS and Ayurvedic line of treatment mentioned in classics.
Introduction to AI for Nonprofits with Tapp NetworkTechSoup
Dive into the world of AI! Experts Jon Hill and Tareq Monaur will guide you through AI's role in enhancing nonprofit websites and basic marketing strategies, making it easy to understand and apply.
This slide is special for master students (MIBS & MIFB) in UUM. Also useful for readers who are interested in the topic of contemporary Islamic banking.
3. Lung Cancer
EDITED BY
Jack A. Roth, MD, F.A.C.S.
Professor and Bud Johnson Clinical Distinguished Chair
Department of Thoracic and Cardiovascular Surgery
Professor of Molecular and Cellular Oncology
Director, W.M. Keck Center for Innovative Cancer Therapies
Chief, Section of Thoracic Molecular Oncology
The University of Texas M.D. Anderson Cancer Center
Houston, Texas, USA
James D. Cox, MD
Professor and Head
Division of Radiation Oncology
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, USA
Waun Ki Hong, MD, D.M.Sc. (Hon.)
American Cancer Society Professor
Samsung Distinguished University Chair in Cancer Medicine
Professor and Head, Division of Cancer Medicine
Professor, Department of Thoracic/Head and Neck Medical Oncology
The University of Texas M.D. Anderson Cancer Center
Houston, Texas, USA
THIRD EDITION
4. C 2008 by Blackwell Publishing
Blackwell Publishing, Inc., 350 Main Street, Malden, Massachusetts 02148-5020, USA
Blackwell Publishing Ltd, 9600 Garsington Road, Oxford OX4 2DQ, UK
Blackwell Publishing Asia Pty Ltd, 550 Swanston Street, Carlton, Victoria 3053, Australia
The right of the Author to be identified as the Author of this Work has been asserted in accordance with
the Copyright, Designs and Patents Act 1988.
All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or
transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or
otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior
permission of the publisher.
First published 1998
Third edition 2008
1 2008
Library of Congress Cataloging-in-Publication Data
Lung cancer / edited by Jack A. Roth, James D. Cox, Waun Ki Hong. – 3rd ed.
p. ; cm.
Includes bibliographical references and index.
ISBN 978-1-4051-5112-2 (alk. paper)
1. Lungs–Cancer. I. Roth, Jack A. II. Cox, James D. (James Daniel), 1938–
III. Hong, Waun Ki.
[DNLM: 1. Lung Neoplasms–therapy. 2. Lung Neoplasms–diagnosis. 3. Lung Neoplasms–genetics.
WF 658 L9604 2008]
RC280.L8L765 2008
616.99 424–dc22
ISBN: 978-1-4051-5112-2
A catalogue record for this title is available from the British Library
Set in 9.5/12pt Meridien by Aptara Inc., New Delhi, India
Printed and bound in Singapore by Fabulous Printers Pte Ltd
For further information on Blackwell Publishing, visit our website:
http://www.blackwellpublishing.com
The publisher’s policy is to use permanent paper from mills that operate a sustainable forestry policy,
and which has been manufactured from pulp processed using acid-free and elementary chlorine-free
practices. Furthermore, the publisher ensures that the text paper and cover board used have met
acceptable environmental accreditation standards.
Designations used by companies to distinguish their products are often claimed as trademarks. All brand
names and product names used in this book are trade names, service marks, trademarks or registered
trademarks of their respective owners. The Publisher is not associated with any product or vendor
mentioned in this book.
The contents of this work are intended to further general scientific research, understanding, and
discussion only and are not intended and should not be relied upon as recommending or promoting a
specific method, diagnosis, or treatment by physicians for any particular patient. The publisher and the
author make no representations or warranties with respect to the accuracy or completeness of the
contents of this work and specifically disclaim all warranties, including without limitation any implied
warranties of fitness for a particular purpose. In view of ongoing research, equipment modifications,
changes in governmental regulations, and the constant flow of information relating to the use of
medicines, equipment, and devices, the reader is urged to review and evaluate the information provided
in the package insert or instructions for each medicine, equipment, or device for, among other things,
any changes in the instructions or indication of usage and for added warnings and precautions. Readers
should consult with a specialist where appropriate. The fact that an organization or Website is referred to
in this work as a citation and/or a potential source of further information does not mean that the author
or the publisher endorses the information the organization or Website may provide or recommendations
it may make. Further, readers should be aware that Internet Websites listed in this work may have
changed or disappeared between when this work was written and when it is read. No warranty may be
created or extended by any promotional statements for this work. Neither the publisher nor the author
shall be liable for any damages arising herefrom.
5. Contents
Contributors, vii
Preface, xi
1 Smoking Cessation, 1
Alexander V. Prokhorov, Kentya H. Ford,
and Karen Suchanek Hudmon
2 Lung Cancer Susceptibility Genes, 20
Joan E. Bailey-Wilson
3 Lung Cancer Susceptibility and Risk Assessment Models, 33
Xifeng Wu, Hushan Yang, Jie Lin, and Margaret R. Spitz
4 The Molecular Genetics of Lung Cancer, 61
David S. Shames, Mitsuo Sato, and John D. Minna
5 Molecular Biology of Preneoplastic Lesions of the Lung, 84
Ignacio I. Wistuba and Adi F. Gazdar
6 Detection of Preneoplastic Lesions, 99
Stephen Lam
7 Treatment of Preneoplastic Lesions of the Lung, 111
Annette McWilliams
8 The Pathology and Pathogenesis of Peripheral Lung Adenocarcinoma
Including Bronchioloalveolar Carcinoma, 121
Wilbur A. Franklin
9 Treatment of Bronchioloalveolar Carcinoma, 144
Ji-Youn Han, Dae Ho Lee, and Jin Soo Lee
10 Molecular Profiling for Early Detection and Prediction of Response
in Lung Cancer, 153
Jacob M. Kaufman and David P. Carbone
11 The Role for Mediastinoscopy in the Staging of Nonsmall Cell
Lung Cancer, 169
Carolyn E. Reed
12 Minimally Invasive Surgery for Lung Cancer, 180
Michael Kent, Miguel Alvelo-Rivera, and James Luketich
13 Extended Resections for Lung Cancer, 194
Philippe G. Dartevelle, Bedrettin Yildizeli, and Sacha Mussot
v
6. vi Contents
14 Adjuvant Chemotherapy Following Surgery for Lung Cancer, 221
Benjamin Besse and Thierry Le Chevalier
15 Induction Chemotherapy for Resectable Lung Cancer, 233
Katherine M.W. Pisters
16 Image-Guided Radiation Therapy, 247
Kenneth E. Rosenzweig and Sonal Sura
17 Stereotactic Body Radiation Therapy for Lung Cancer, 256
Robert D. Timmerman and Brian D. Kavanagh
18 Proton Therapy, 271
Joe Y. Chang, Alfred R. Smith, and James D. Cox
19 Combinations of Radiation Therapy and Chemotherapy for
Nonsmall Cell Lung Carcinoma, 283
Zhongxing Liao, Frank V. Fossella, and Ritsuko Komaki
20 New Chemotherapeutic Agents in Lung Cancer, 315
Anne S. Tsao
21 Immunologic Approaches to Lung Cancer Therapy, 334
Jay M. Lee, Steven M. Dubinett, and Sherven Sharma
22 Epidermal Growth Factor Receptor Inhibitors, 352
Lecia V. Sequist and Thomas J. Lynch
23 Tumor Angiogenesis: Biology and Therapeutic Implications
for Lung Cancer, 369
Emer O. Hanrahan, Monique Nilsson, and John V. Heymach
24 Retinoids and Rexinoids in Lung Cancer Prevention and Treatment, 386
Nishin Bhadkamkar and Fadlo R. Khuri
25 Proteasome Inhibition in Nonsmall Cell Lung Cancer Therapy, 400
Minh Huynh and Primo N. Lara Jr
26 Targeted Genetic Therapy for Lung Cancer, 411
Jack Roth
27 Screening for Early Detection, 421
James L. Mulshine
28 Natural Agents for Chemoprevention of Lung Cancer, 441
Amir Sharafkhaneh, Suryakanta Velamuri,
Seyed Javad Moghaddam, Vladimir Badmaev,
Burton Dickey, and Jonathan Kurie
Index, 457
Color plates are found facing, 276
7. Contributors
Miguel Alvelo-Rivera, MD James D. Cox, MD
Assistant Professor of Surgery, Professor and Head, Division of Radiation Oncology
Division of Thoracic Surgery The University of Texas,
University of Pittsburgh Medical Center, M.D. Anderson Cancer Center,
Pittsburgh, PA, USA Houston, TX, USA
Vladimir Badmaev, MD Philippe G. Dartevelle, MD
Vice President, Scientific and Medical Affairs Professor of Thoracic and Cardiovascular Surgery
Sabinsa Pharmaceutical, Inc., at Paris Sud University
New Jersey, NJ, USA Head of the Department of Thoracic
and Vascular Surgery and Heart Lung Tansplantation
Joan E. Bailey-Wilson, PhD ˆ
Hopital Marie Lannelongue Le Plessis
Senior Investigator and Co-Branch Chief, Robinson France
National Human Genome Research Institute,
National Institutes of Health, Burton Dickey, MD
Baltimore, MD, USA Professor and Chair,
Department of Pulmonary Medicine
Benjamin Besse, MD The University of Texas
Assistant Professor, M. D. Anderson Cancer Center
Department of Medicine, Houston, TX, USA
Institut Gustave Roussy,
Villejuif, France Steven M. Dubinett, MD
Professor and Chief
Nishin Bhadkamkar Division of Pulmonary and Critical Care Medicine,
Resident, House Staff Doctor Department of Medicine,
Emory University School of Medicine Director, UCLA Lung Cancer Research Program,
Atlanta, GA, USA Jonsson Comprehensive Cancer Center,
David Geffen School of Medicine at UCLA,
David P. Carbone, MD, PhD Los Angeles, CA, USA
Professor of Medicine and Cancer Biology,
Vanderbilt-Ingram Cancer Center, Kentya H. Ford, PhD
Nashville, TN, USA Postdoctoral Fellow,
Department of Behavioral Sicence,
Joe Y. Chang, MD, PhD The University of Texas,
Assistant Professor, M. D. Anderson Cancer Center,
Director of Translation Research in Houston, TX, USA
Thoracic Radiation Oncology,
Department of Radiation Oncology, Frank Fosella, MD
The University of Texas M. D. Anderson Cancer Center, Medical Director, Thoracic Oncology
Houston, TX, USA Multidisciplinary Care Center;
Professor, Department of Thoracic/Head
Thierry Le Chevalier, MD and Neck Medical Oncology
Department of Medicine, The University of Texas,
Institut Gustave Roussy, M.D. Anderson Cancer Center
Villejuif, France Houston, TX , USA
vii
8. viii Contributors
Wilbur A. Franklin, MD Michael Kent, MD
Professor, Department of Pathology, Surgical Resident, Department of
University of Colorado Health Sciences Center, Thoracic Surgery,
Aurora, CO, USA Beth Israel Deaconess Medical Center,
Boston, MA, USA
Adi F. Gazdar, MD
Professor of Pathology and Deputy Director, Fadlo R. Khuri, MD
Hamon Center for Therapeutic Oncology Research, Professor of Hematology and Oncology,
The University of Texas Southwestern Medical Center, Winship Cancer Institute,
Dallas, TX, USA Emory University,
Atlanta, GA, USA
Ji-Youn Han, MD, PhD
Chief Scientist, Lung Cancer Branch, Ritsuko Komaki, MD
National Cancer Center Professor, Department of Radiation
Goyang, Gyeonggi, Korea Oncology,
Gloria Lupton Tennison Distinguished
Emer O. Hanrahan, MB, BCh, MRCPI Professorship for Lung Cancer Resarch
Medical Oncology Fellow, The University of Texas,
Department of Thoracic/Head and M. D. Anderson Cancer Center,
Neck Medical Oncology, Houston, TX, USA
The University of Texas M.D. Anderson
Cancer Center,
Jonathan Kurie, MD
Houston, TX, USA
Professor, Department of Thoracic/Head
and Neck Medical Oncology
John Heymach, MD, PhD
The University of Texas,
Assistant Professor,
M.D. Anderson Cancer Center
Department of Thoracic/Head and Neck Medical Oncology
Houston, TX, USA
and Cancer Biology
The University of Texas,
M.D. Anderson Cancer Center
Stephen Lam, MD, FRCPC
Professor of Medicine,
Houston, TX , USA
University of British Columbia;
and Chair, Lung Tumor Group,
Karen Suchanek Hudmon, Dr PH, MS, BS Pharm
British Columbia Cancer Agency,
Associate Professor,
Vancouver, British Columbia, Canada
Department of Pharmacy Practice,
Purdue University School of Pharmacy &
Pharmaceutical Sciences, Primo N. Lara Jr, MD
West, Lafavette, Professor of Medicine,
IN, USA University of California Davis
Cancer Center, Sacramento, CA, USA
Minh Huynh, MD
Staff Oncologist Dae Ho Lee, MD
Kaiser Permanente Walnut Creek Medical Center, Assistant Professor,
Walnut Creek, CA Division of Oncology,
Department of Internal Medicine,
Jacob M. Kaufman, MD, PhD College of Medicine,
Candidate, Predoctoral Trainee University of Ulsan and Asan Medical
Vanderbilt University School of Medicine Center,
Vanderbilt University Cancer Center, Seoul, Korea
Nashville, TN, USA
Jay M. Lee, MD
Brian D. Kavanagh, MD, MPH Surgical Director, Thoracic Oncology Program
Professor and Vice Chairman, Assistant Professor of Surgery
Department of Radiation Oncology, Division of Cardiothoracic Surgery
University of Colorado Comprehensive Cancer Center, David Geffen School of Medicine at UCLA
Aurora, CO, USA Los Angeles, CA, USA
9. Contributors ix
Jin Soo Lee, MD Sacha Mussot, MD
Director, Thoracic and Vascular Surgeon and Staff Member
Research Institute, Department of Thoracic and Vascular Surgery
National Cancer Center, and Heart Lung Transplantation
Goyang, Gyeonggi, Korea ˆ
Hopital Marie Lannelongue – Le Plessis Robinson – France
Zhongxing Liao, MD Monique B. Nilsson, PhD
Associate Professor, Research Scientist,
The University of Texas M.D. Department of Cancer Biology,
Anderson Cancer Center, The University of Texas M.D. Anderson Cancer Center,
Houston, TX, USA Houston, TX, USA
Jie Lin, PhD Katherine M.W. Pisters, MD
Instructor, Department of Epidemiology, Professor of Medicine,
The University of Texas M.D. Anderson Cancer Center, Department of Thoracic/Head & Neck Medical
Houston, TX, USA Oncology,
Division of Cancer Medicine,
James D. Luketich, MD
The University of Texas M.D. Anderson Cancer
Sampson Endowed Professor of Surgery;
Center,
and Chief, Heart,
Houston, TX, USA
Lung and Esophageal Surgery Institute,
University of Pittsburgh
Alexander V. Prokhorov, MD, PhD
Medical Center,
Professor, Department of Behavioral Science,
Pittsburgh, PA, USA
The University of Texas M.D. Anderson Cancer
Center,
Thomas J. Lynch
Houston, TX, USA
Chief of Hematology–Oncology,
Massachusetts General Hospital,
Carolyn E. Reed, MD
Boston, MA, USA
Professor of Surgery and Chief,
Annette McWilliams, MD, FRCPC Section of General Thoracic Surgery,
Clinical Assistant Professor, Medical University of South Carolina,
Department of Medicine, Charleston, SC, USA
University of British Columbia;
and Respiratory Physician, Kenneth E. Rosenzweig, MD
Department of Cancer Imaging, Associate Attending,
BC Cancer Research Centre, Department of Radiation Oncology,
Vancouver, BC, Canada Memorial Sloan–Kettering Cancer Center,
New York, NY, USA
John D. Minna, MD
Professor of Internal Medicine and Pharmacology; Jack Roth, MD
and Director, Hamon Center for Therapeutic Professor and Bud Johnson Clinical Distinguished Chair
Oncology Research, Department of Thoracic and Cardiovascular Surgery
The University of Texas Southwestern Medical Center, Professor of Molecular and Cellular Oncology
Dallas, TX, USA Director, W.M. Keck Center for Innovative Cancer
Therapies
Seyed Javad Moghaddam, MD Chief, Section of Thoracic Molecular Oncology
Instructor, Department of Pulmonary Medicine The University of Texas,
The University of Texas, M.D. Anderson Cancer Center
M.D. Anderson Cancer Center, Houston, TX, USA
Houston, TX, USA
Mitsuo Sato, MD, PhD
James L. Mulshine, MD Postdoctoral Researcher,
Professor, Internal Medicine and Associate Provost Hamon Center for Therapeutic Oncology Research
for Research, and the Simmons Cancer Center,
Rush University Medical Center, The University of Texas Southwestern Medical Center,
Chicago, IL, USA Dallas, TX, USA
10. x Contributors
Lecia Sequist, MD, MPH Robert D. Timmerman, MD
Instructor in Medicine, Professor and Vice Chairman,
Harvard Medical School, Effie Marie Cain Distinguished Chair
MGH Cancer Center, in Cancer Therapy Research,
Boston, MA, USA Department of Radiation Oncology,
University of Texas
David S. Shames, PhD Southwestern Medical Center,
Postdoctoral Fellow Dallas, TX, USA
Hamon Center for Therapeutic Oncology Research
The University of Texas Southwestern Medical Center, Anne S. Tsao, MD
Dallas, TX, USA Assistant Professor,
Department of Thoracic/Head and
Amir Sharafkhaneh, MD Neck Medical Oncology,
Assistant Professor of Medicine at Baylor College The University of Texas
of Medicine and Staff, M.D. Anderson Cancer Center,
Physician at the Michael E. DeBakey VA Medical Center, Houston, TX, USA
Houston, TX, USA
Suryakanta Velamuri, MD
Sherven Sharma, PhD Assistant Professor of Medicine,
Associate Professor, Balor College of Medicine;
Division of Pulmonary and Critical and Staff Physician,
Care Medicine, Michael E. Debakey VA Medical Center,
Department of Medicine, Houston, TX, USA
UCLA Lung Cancer Research Program,
David Geffen School of Medicine at UCLA, Ignacio I. Wistuba, MD
West Los Angeles VA, Associate Professor of Pathology
Los Angeles, CA, USA and Thoracic/Head & Neck Medical
Oncology,
Alfred R. Smith, PhD The University of Texas
Professor, The University of Texas M.D. Anderson Cancer Center,
M.D. Anderson Proton Therapy Center, Houston, TX, USA
Houston, TX, USA
Xifeng Wu, MD, PhD
Margaret R. Spitz, MD, MPH Professor, Department of Epidemiology,
Professor and Chair, The University of Texas
Department of Epidemiology, M.D. Anderson Cancer Center,
The University of Texas Houston, TX, USA
M.D. Anderson Cancer Center,
Houston, TX, USA Bedrettin Yildizeli, MD
Associated Professor of Thoracic Surgery,
Sonal Sura, MD Department of Thoracic Surgery,
Radiation Oncology Resident, Marmara University Hospital,
New York City, NY, USA Istanbul, Turkey
11. Preface
When the first edition of Lung Cancer was pub- high risk for developing lung cancer. This will be
lished 14 years ago, the editors were optimistic that important for implementing screening and preven-
progress in reducing the mortality from this disease tion strategies. New techniques have emerged for
would result from insights in the biology of can- lung cancer staging that improve accuracy. A va-
cer and new treatment strategies. Rapid progress in riety of surgical and radiation therapy techniques
the biology, prevention, diagnosis, and treatment have been developed which will make local tumor
of lung cancer convinced us that a third edition control more effective and less invasive. Combined
was warranted. This book is not intended as a com- modality therapy and new chemotherapeutic agents
prehensive textbook, but as a concise summary of are yielding higher response rates and improved sur-
advances in lung cancer clinical research and treat- vival when used in the adjuvant setting. The final
ment for the clinician. section of the book describes novel approaches that
Over 20 years of research on the biology of lung may emerge as important preventative, diagnostic,
cancer has culminated in the clinical application and therapeutic modalities in the near future.
of targeted therapies. These agents disable specific The editors emphasize that these advances are
oncogenic pathways in the lung cancer cell and possible because of the work of those dedicated
can mediate tumor regression with fewer adverse to translational research and rigorously conducted
events. Several chapters are devoted to summariz- clinical trials. We are optimistic that progress will
ing the most recent work in this field. Much research continue at a rapid pace and that deaths from lung
is attempting to identify biomarkers to predict a cancer will continue to decrease.
Jack A. Roth
James D. Cox
Waun Ki Hong
xi
12. CHAPTER 1
Smoking Cessation
Alexander V. Prokhorov, Kentya H. Ford, and Karen Suchanek Hudmon
Overview resulting in nearly 440,000 deaths each year [3].
The economic implications are enormous: more
Tobacco use is a public health issue of enormous than $75 billion in medical expenses and over $81
importance, and smoking is the primary risk factor billion in loss of productivity as a result of pre-
for the development of lung cancer. Considerable mature death are attributed to smoking each year
knowledge has been gained with respect to biobe- [4–8]. While the public often associates tobacco use
havioral factors leading to smoking initiation and with elevated cancer risk, the negative health con-
development of nicotine dependence. Smoking ces- sequences are much broader. The 2004 Surgeon
sation provides extensive health benefits for every- General’s Report on the health consequences of
one. State-of-the-art treatment for smoking cessa- smoking [9] provides compelling evidence of the ad-
tion includes behavioral counseling in conjunction verse impact of smoking and concluded that smok-
with one or more FDA-approved pharmaceutical ing harms nearly every organ in the body (Table
aids for cessation. The US Public Health Service Clin- 1.1). In 2000, 8.6 million persons in the United
ical Practice Guideline for Treating Tobacco Use and De- States were living with an estimated 12.7 mil-
pendence advocates a five-step approach to smoking lion smoking-attributable medical conditions [10].
cessation (Ask about tobacco use, Advise patients to There is convincing evidence that stopping smok-
quit, Assess readiness to quit, Assist with quitting, ing is associated with immediate as well as long-
and Arrange follow-up). Health care providers are term health benefits, including reduced cumulative
encouraged to provide at least brief interventions at risk for cancer. This is true even in older individu-
each encounter with a patient who uses tobacco. als, and in patients who have been diagnosed with
cancer [11].
Introduction
Smoking and lung cancer
More than two decades ago, the former US Surgeon
General C. Everett Koop stated that cigarette smok- In the United States, approximately 85% of all
ing is the “chief, single, avoidable cause of death in lung cancers are in people who smoke or who
our society and the most important public health have smoked [3]. Lung cancer is fatal for most
issue of our time” [1]. This statement remains true patients. The estimated number of deaths of lung
today. In the United States, cigarette smoking is the cancer will exceed 1.3 million annually early in the
primary known cause of preventable deaths [2], third millennium [12]. Lung cancer is the leading
cause of cancer-related deaths among Americans
Lung Cancer, 3rd edition. Edited by Jack A. Roth, James D. Cox,
of both genders, with 174,470 estimated newly
and Waun Ki Hong. c 2008 Blackwell Publishing, diagnosed cases and 162,460 deaths [13,14]. The
ISBN: 978-1-4051-5112-2. number of deaths due to lung cancer exceeds the
1
13. 2 Chapter 1
Table 1.1 Health consequences of smoking. annual number of deaths from breast, colon, and
prostate cancer combined [15]. Recent advances in
Cancer Acute myeloid leukemia
technology have enabled earlier diagnoses, and ad-
Bladder
vances in surgery, radiation therapy, imaging, and
Cervical
Esophageal chemotherapy have produced improved responses
Gastric rates. However, despite these efforts, overall sur-
Kidney vival has not been appreciably affected in 30 years,
Laryngeal and only 12–15% of patients with lung cancer are
Lung being cured with current treatment approaches
Oral cavity and pharyngeal
[16]. The prognosis of lung cancer depends largely
Pancreatic
on early detection and immediate, premetastasis
Cardiovascular Abdominal aortic aneurysm
stage treatment [17]. Prevention of lung cancer
diseases Coronary heart disease (angina pectoris, is the most desirable and cost-efficient approach
ischemic heart disease, myocardial
to eradicating this deadly condition. Numerous
infarction, sudden death)
epidemiologic studies consistently define smoking
Cerebrovascular disease (transient
as the major risk factor for lung cancer (e.g. [18–
ischemic attacks, stroke)
20]). The causal role of cigarette smoking in lung
Peripheral arterial disease
cancer mortality has been irrefutably established
Pulmonary Acute respiratory illnesses in longitudinal studies, one of which lasted as long
diseases Pneumonia
as 50 years [21]. Tobacco smoke, which is inhaled
Chronic respiratory illnesses either directly or as second-hand smoke, contains
Chronic obstructive pulmonary
an estimated 4000 chemical compounds, including
disease
over 60 substances that are known to cause cancer
Respiratory symptoms (cough,
[22]. Tobacco irritants and carcinogens damage the
phlegm, wheezing, dyspnea)
cells in the lungs, and over time the damaged cells
Poor asthma control
may become cancerous. Cigarette smokers have
Reduced lung function in infants lower levels of lung function than nonsmokers
exposed (in utero) to maternal
[9,23], and quitting smoking greatly reduces
smoking
cumulative risk for developing lung cancer [24].
Reproductive Reduced fertility in women
The association of smoking with the development
effects Pregnancy and pregnancy outcomes of lung cancer is the most thoroughly documented
Premature rupture of membranes
causal relationship in biomedical history [25]. The
Placenta previa
Placental abruption
link was first observed in the early 1950s through
Preterm delivery the research of Sir Richard Doll, whose pioneering
Low infant birth weight research has, perhaps more so than any other epi-
Infant mortality (sudden infant death demiologist of his time, altered the landscape of dis-
syndrome) ease prevention and consequently saved millions of
Other Cataract lives worldwide. In two landmark US Surgeon Gen-
effects Osteoporosis (reduced bone density in erals’ reports published within a 20-year interval (in
postmenopausal women, increased risk 1964 [26] and in 2004 [9]), literature syntheses fur-
of hip fracture) ther documented the strong link between smoking
Periodontitis and cancer. Compared to never smokers, smokers
Peptic ulcer disease (in patients who are have a 20-fold risk of developing lung cancer, and
infected with Helicobacter pylori) more than 87% of lung cancers are attributable to
Surgical outcomes smoking [27]. The risk for developing lung cancer
Poor wound healing increases with younger age at initiation of smoking,
Respiratory complications greater number of cigarettes smoked, and greater
number of years smoked [11]. Women smoking the
Source: Reference [9].
14. Smoking Cessation 3
same amount as men experience twice the risk of Smoking among lung
developing lung cancer [28,29]. cancer patients
Tobacco use among patients with cancer is a se-
Second-hand smoke and rious health problem with significant implications
lung cancer for morbidity and mortality [36–39]. Evidence in-
dicates that continued smoking after a diagnosis
While active smoking has been shown to be the with cancer has substantial adverse effects on treat-
main preventable cause of lung cancer, second- ment effectiveness [40], overall survival [41], risk
hand smoke contains the same carcinogens that are of second primary malignancy [42], and increases
inhaled by smokers [30]. Consequently, there has the rate and severity of treatment-related complica-
been a concern since release of the 1986 US Sur- tions such as pulmonary and circulatory problems,
geon General’s report [31] concluding that second- infections, impaired would healing, mucositis, and
hand smoke causes cancer among nonsmokers and Xerostomia [43,44].
smokers. Although estimates vary by exposure lo- Despite the strong evidence for the role of smok-
cation (e.g., workplace, car, home), the 2000 Na- ing in the development of cancer, many cancer pa-
tional Household Interview Survey estimates that a tients continue to smoke. Specifically, about one
quarter of the US population is exposed to second- third of cancer patients who smoked prior to their
hand smoke [32]. Second-hand smoke is the third diagnoses continue to smoke [45] and among pa-
leading cause of preventable deaths in the United tients received surgical treatment of stage I nonsmall
States [33], and it has been estimated that expo- cell lung cancer [46] found only 40% who were ab-
sure to second-hand smoke kills more than 3000 stinent 2 years after surgery. Davison and Duffy [47]
adult nonsmokers from lung cancer [34]. Accord- reported that 48% of former smokers had resumed
ing to Glantz and colleagues, for every eight smok- regular smoking after surgical treatment of lung
ers who die from a smoking-attributable illness, one cancer. Therefore, among patients with smoking-
additional nonsmoker dies because of second-hand related malignancies, the likelihood of a positive
smoke exposure [35]. smoking history at and after diagnosis is high.
Since 1986, numerous additional studies have Patients who are diagnosed with lung cancer may
been conducted and summarized in the 2006 US face tremendous challenges and motivation to quit
Surgeon General’s report on “The Health Conse- after a cancer diagnosis can be influenced by a range
quences of Involuntary Exposure of Tobacco Smoke.” The of psychological variables. Schnoll and colleagues
report’s conclusions based on this additional ev- [48] reported that continued smoking among pa-
idence are consistent with the previous reports: tients with head and neck and lung cancer is asso-
exposure to second-hand smoke increases risk of ciated with lesser readiness to quit, having relatives
lung cancer. More than 50 epidemiologic stud- who smoke at home, greater time between diag-
ies of nonsmokers’ cigarette smoke exposure at noses and assessment, greater nicotine dependence,
the household and/or in the workplace showed lower self-efficacy, lower risk perception, fewer per-
an increased risk of lung cancer associated with ceived pros and greater cons to quitting, more fa-
second-hand smoke exposure [34]. This means that talistic beliefs, and higher emotional distress. Lung
20 years after second-hand smoke was first es- cancer patients should be advised to quit smoking,
tablished as a cause of lung cancer in lifetime but once they are diagnosed, some might feel that
nonsmokers, the evidence supporting smoking ces- there is nothing to be gained from quitting [49].
sation and reduction of second-hand smoke expo- Smoking cessation should be a matter of special
sure continues to mount. Eliminating second-hand concern throughout cancer diagnosis, treatment,
smoke exposure at home, in the workplaces, and and the survival continuum, and the diagnosis of
other public places appears to be essential for re- cancer should be used as a “teachable moment”
ducing the risk of lung cancer development among to encourage smoking cessation among patients,
nonsmokers. family members, and significant others [37]. The
15. 4 Chapter 1
Table 1.2 Percentage of current cigarette smokersa aged ≥18 years, by selected characteristics—National Health
Interview Survey, United States, 2005.
Characteristic Category Men (n = 13,762) Women (n = 17,666) Total (n = 31,428)
Race/ethnicityb White, non-Hispanic 24.0 20.0 21.9
Black, non-Hispanic 26.7 17.3 21.5
Hispanic 21.1 11.1 16.2
American Indian/Alaska Native 37.5 26.8 32.0
Asianc 20.6 6.1 13.3
Educationd 0–12 years (no diploma) 29.5 21.9 25.5
GEDe (diploma) 47.5 38.8 43.2
High school graduate 28.8 20.7 24.6
Associate degree 26.1 17.1 20.9
Some college (no degree) 26.2 19.5 22.5
Undergraduate degree 11.9 9.6 10.7
Graduate degree 6.9 7.4 7.1
Age group (yrs) 18–24 28.0 20.7 24.4
25–44 26.8 21.4 24.1
45–64 25.2 18.8 21.9
≥65 8.9 8.3 8.6
Poverty levelf At or above 23.7 17.6 20.6
Below 34.3 26.9 29.9
Unknown 21.2 16.1 18.4
Total 23.9 18.1 20.9
a
Persons who reported having smoked at least 100 cigarettes during their lifetime and at the time of the interview reported
smoking every day or some days; excludes 296 respondents whose smoking status was unknown.
b
Excludes 314 respondents of unknown or multiple racial/ethnic categories or whose racial/ethnic category was unknown.
c
Excludes Native Hawaiians or other Pacific Islanders.
d
Persons aged ≥25 years, excluding 339 persons with unknown level of education.
e
General Educational Development.
f
Calculated on the basis of US Census Bureau 2004 poverty thresholds.
Source: Reference [7].
medical, psychosocial, and general health benefits proportion of the population continues to smoke.
of smoking cessation for cancer patients provide a In 2005, an estimated 45.1 million adult Americans
clear rationale for intervention. (20.9%) were current smokers; of these, 80.8% re-
ported to smoking every day, and 19.2% reported
smoking some days [7]. The prevalence of smoking
Forms of tobacco varies considerably across populations (Table 1.2),
with a greater proportion of men (23.9%) than
Smoked tobacco women (18.1%) reporting current smoking. Per-
Cigarettes have been the most widely used form of sons of Asian or Hispanic origin exhibit the low-
tobacco in the United States for several decades [51], est prevalence of smoking (13.3 and 16.2%, respec-
yet in recent years, cigarette smoking has been de- tively), and American Indian/Alaska natives exhibit
clining steadily among most population subgroups. the highest prevalence (32.0%). Also, the preva-
In 2005, just over half of ever smokers reported be- lence of smoking among adults varies widely across
ing former smokers [3]. However, a considerable the United States, ranging from 11.5% in Utah to
16. Smoking Cessation 5
28.7% in Kentucky [51]. Twenty-three percent of less tobacco than standard cigarettes, bidis expose
high school students report current smoking, and their smokers to considerable amounts of hazardous
among boys, 13.6% report current use of smoke- compounds. A smoking machine-based investiga-
less tobacco, and 19.2% currently smoke cigars [52]. tion found that bidis deliver three times the amount
These figures are of particular concern, because of carbon monoxide and nicotine and almost five
nearly 90% of smokers begin smoking before the times the amount of tar found in conventional
age of 18 years [53]. cigarettes [63].
Other common forms of burned tobacco in the
United States include cigars, pipe tobacco, and bidis. Smokeless tobacco
Cigars represent a roll of tobacco wrapped in leaf to- Smokeless tobacco products, also commonly called
bacco or in any substance containing tobacco [54]. “spit tobacco,” are placed in the mouth to allow ab-
Cigars’ popularity has somewhat increased over the sorption of nicotine through the buccal mucosa. Spit
past decade [55]. The latter phenomenon is likely tobacco includes chewing tobacco and snuff. Chew-
to be explained by a certain proportion of smok- ing tobacco, which is typically available in loose leaf,
ers switching cigarettes for cigars and by adoles- plug, and twist formulations, is chewed or parked in
cents’ experimentation with cigars [56]. In 1998, the cheek or lower lip. Snuff, commonly available as
approximately 5% of adults had smoked at least one loose particles or sachets (resembling tea bags), has
cigar in the past month [57]. The nicotine content a much finer consistency and is generally held in
of cigars sold in the United States ranged from 5.9 the mouth and not chewed. Most snuff products
to 335.2 mg per cigar [58] while cigarettes have a in the United States are classified as moist snuff.
narrow range of total nicotine content, between 7.2 The users park a “pinch” (small amount) of snuff
and 13.4 mg per cigarette [59]. Therefore, one large between the cheek and gum (also known as dip-
cigar, which could contain as much tobacco as an ping) for 30 minutes or longer. Dry snuff is typically
entire pack of cigarettes is able to deliver enough sniffed or inhaled through the nostrils; it is used less
nicotine to establish and maintain physical depen- commonly [64].
dence [59]. In 2004, an estimated 3.0% of Americans 12 years
Pipe smoking has been declining steadily over the of age and older had used spit tobacco in the past
past 50 years [60]. It is a form of tobacco use seen month. Men used it at higher rates (5.8%) than
among less than 1% of Americans [60]. Bidi smok- women (0.3%) [60]. The prevalence of spit tobacco
ing is a more recent phenomenon in the United is the highest among 18- to 25-year-olds and is sub-
States. Bidis are hand-rolled brown cigarettes im- stantially higher among American Indians, Alaska
ported mostly from Southeast Asian countries. Bidis natives, residents of the southern states, and ru-
are wrapped in a tendu or temburni leaf [61]. Visually, ral residents [61,66]. The consumption of chew-
they somewhat resemble marijuana joints, which ing tobacco has been declining since the mid-1980s;
might make them attractive to certain groups of conversely, in 2005, snuff consumption increased by
the populations. Bidis are available in multiple fla- approximately 2% over the previous year [66], pos-
vors (e.g., chocolate, vanilla, cinnamon, strawberry, sibly because tobacco users are consuming snuff in-
cherry, mango, etc.), which might make them par- stead of cigarettes in locations and situations where
ticularly attractive to younger smokers. A survey smoking is banned.
of nearly 64,000 people in 15 states in the United
States revealed that young people (18–24 years of
age) reported higher rates of ever (16.5%) and Factors explaining tobacco use
current (1.4%) use of bidis then among older adults
(ages 25 plus years). With respect to sociodemo- Smoking initiation
graphic characteristics, the use of bidis is most com- In the United States, smoking initiation typically
mon among males, African Americans, and con- occurs during adolescence. About 90% of adult
comitant cigarette smokers [62]. Although featuring smokers have tried their first cigarette by 18 years
17. 6 Chapter 1
of age and 70% of daily smokers have become tine acts on the brain to produce a number of ef-
regular smokers by that age [67,68]. Because most fects [77,78] and immediately after exposure, nico-
adolescents who smoke at least monthly continue tine induces a wide range of central nervous sys-
to smoke into adulthood, youth-oriented tobacco tem, cardiovascular, and metabolic effects. Nicotine
preventions and cessation strategies are warranted stimulates the release of neurotransmitters, in-
[67,68]. Since the mid-1990s, by 2004, the past- ducing pharmacologic effects, such as pleasure
month prevalence had decreased by 56% in 8th and reward (dopamine), arousal (acetylcholine,
graders, 47% in 10th graders, and 32% in 12th norepinephrine), cognitive enhancement (acetyl-
graders [69]. In recent years, however, this down- choline), appetite suppression (norepinephrine),
ward trend has decelerated [69]. The downward learning and memory enhancement (glutamate),
trend is unlikely to be sustained without steady and mood modulation and appetite suppression (sero-
systematic efforts by health care providers in pre- tonin), and reduction of anxiety and tension
venting initiation of tobacco use and assisting young (β-endorphin and GABA) [78]. Upon entering the
smokers in quitting. brain, a bolus of nicotine activates the dopamine re-
A wide range of sociodemographic, behavioral, ward pathway, a network of nervous tissue in the
personal, and environmental factors have been ex- brain that elicits feelings of pleasure and stimulates
amined as potential predictors of tobacco exper- the release of dopamine.
imentation and initiation of regular tobacco use Although withdrawal symptoms are not the only
among adolescents. For example, it has been sug- consequence of abstinence, most cigarette smok-
gested that the prevalence of adolescent smok- ers do experience craving and withdrawal on ces-
ing is related inversely to parental socioeconomic sation [79], and, therefore, relapse is common [80].
status and adolescent academic performance [68]. The calming effect of nicotine reported by many
Other identified predictors of adolescent smoking users is usually associated with a decline in with-
include social influence and normative beliefs, neg- drawal effects rather than direct effects on nicotine
ative affect, outcome expectations associated with [53]. This rapid dose-response, along with the short
smoking, resistance skills (self-efficacy), engaging in half-life of nicotine (t 1/2 = 2 h), underlies tobacco
other risk-taking behaviors, exposure to smoking in users’ frequent, repeated administration, thereby
movies, and having friends who smoke [70–75]. perpetuating tobacco use and dependence. Tobacco
Although numerous studies have been successful users become proficient in titrating their nicotine
in identifying predictors of smoking initiation, few levels throughout the day to avoid withdrawal
studies have identified successful methods for pro- symptoms, to maintain pleasure and arousal, and
moting cessation among youth, despite the finding to modulate mood. Withdrawal symptoms include
that in 2005, more than half of high school cigarette depression, insomnia, irritability/frustration/anger,
smokers have tried to quit smoking in the past year anxiety, difficulty concentrating, restlessness, in-
and failed [52]. These results confirm the highly creased appetite/weight gain, and decreased heart
addictive nature of tobacco emphasizing the need rate [81,82].
for more effective methods for facilitating cessation The assumption that heavy daily use (i.e., 15–
among the young. 30 cigarettes per day), is necessary for dependence
to develop is derived from observations of “chip-
Nicotine addiction pers,” adult smokers who have not developed de-
Nicotine has come to be regarded as a highly addic- pendence despite smoking up to five cigarettes per
tive substance. Judging by the current diagnostic cri- day for many years [83,84]. Chippers do not tend
teria, tobacco dependence appears to be quite preva- to differ from other smokers in their absorption and
lent among cigarette smokers; more than 90% of metabolism of nicotine, causing some investigators
smokers meet the DSM-IV (Diagnostic and Statisti- to suggest that this level of consumption may be too
cal Manual of Mental Disorders) criteria for nicotine low to cause nicotine dependence. However, these
dependence [76]. Research has shown that nico- atypical smokers are usually eliminated from most
18. Smoking Cessation 7
studies, which are routinely limited to smokers of smoked, number of cigarettes smoked per day) will
at least 10 cigarettes per day [83]. be more similar for persons who are related geneti-
Signs of dependence on nicotine have been re- cally (i.e., biologically) than for persons who are not
ported among adolescent smokers, with approx- related genetically. Hence, one would expect to ob-
imately one fifth of them exhibiting adult-like serve greater similarities between children and their
dependence [85]. Although, lengthy and regular biological parents and siblings than would be ob-
tobacco use has been considered necessary for served between children and their adoptive parents
nicotine dependence to develop [68], recent re- or adopted siblings. Indeed, research has demon-
ports have raised concerns that nicotine depen- strated stronger associations (i.e., higher correlation
dence symptoms can develop soon after initiation, coefficients) between biologically-related individu-
and that these symptoms might lead to smoking als, compared to nonbiologically-related individu-
intensification [79,86]. Adolescent smokers, who als, for the reported number of cigarettes consumed
use tobacco regularly, tend to exhibit high craving [90]. In recent years, it has become more difficult
for cigarettes and substantial levels of withdrawal to conduct adoption studies, because of the reduced
symptoms [87]. number of intranational children available for adop-
tion [91]. Additionally, delayed adoption (i.e., time
elapsed between birth and entry into the new fam-
Genetics of tobacco use and ily) is common with international adoptions and
dependence might lead to an overestimation of genetic effects
if early environmental influences are attributed to
As early as 1958, Fisher hypothesized that the link genetic influences [92].
between smoking and lung cancer could be ex- In twin studies, identical (monozygotic) twins
plained at least in part by shared genes that predis- and fraternal (dizygotic) twins are compared. Iden-
pose individuals to begin smoking as young adults tical twins share the same genes; fraternal twins,
and to develop lung cancer later in adulthood [88]. like ordinary siblings, share approximately 50% of
More recently, tobacco researchers have begun to their genes. If a genetic link exists for the phe-
explore whether genetic factors do in fact contribute nomenon under study, then one would expect to
toward tobacco use and dependence. see a greater concordance in identical twins than
Tobacco use and dependence are hypothesized to in fraternal twins. Thus, in the case of tobacco
result from an interplay of many factors (includ- use, one would expect to see a greater proportion
ing pharmacologic, environmental and physiologic) of identical twins with the same tobacco use be-
[77]. Some of these factors are shared within fam- havior than would be seen with fraternal twins.
ilies, either environmentally or genetically. Studies Statistically, twin studies aim to estimate the per-
of families consistently demonstrate that, compared centage of the variance in the behavior that is
to family members of nonsmokers, family members due to (1) genes (referred to as the “heritability”),
of smokers are more likely to be smokers also. How- (2) shared (within the family) environmental ex-
ever, in addition to shared genetic predispositions, periences, and (3) nonshared (external from the
it is important to consider environmental factors family) environmental experiences [91]. A num-
that promote tobacco use—siblings within the same ber of twin studies of tobacco use have been con-
family share many of the same environmental in- ducted in recent years. These studies have largely
fluences as well as the same genes. To differentiate supported a genetic role [91,93]; higher concor-
the genetic from the environmental influences, epi- dance of tobacco use behavior is evident in identical
demiologists use adoption, twin, twins reared apart, twins than in fraternal twins. The estimated aver-
and linkage study designs [89]. age heritability for smoking is 0.53 (range, 0.28–
Key to the adoption studies is the assumption that 0.84) [93,94]; approximately half of the variance
if a genetic link for tobacco use exists, then tobacco in smoking appears to be attributable to genetic
use behaviors (e.g., smoking status, number of years factors.
19. 8 Chapter 1
Recent advances in the mapping of the human metabolism via the cytochrome P450 liver enzymes
genome have enabled researchers to search for (specifically, CYP2A6 and CYP2D6).
genes associated with specific disorders, including In summary, each of these types of study designs
tobacco use. Using a statistical technique called link- supports the hypothesis that genetics influence the
age analysis, it is possible to identify genes that pre- risk for a wide range of tobacco-related phenotypes,
dict a trait or disorder. This process is not based on such as ever smoking, age at smoking onset, level
prior knowledge of a gene’s function, but rather it of smoking, ability to quit, and the metabolic path-
is determined by examining whether the trait or ways of nicotine (e.g., see [45,89,95–99]). But given
disorder is coinherited with markers found in spec- that there are many predictors of tobacco use and
ified chromosomal regions. Typically, these types dependence, of which genetic predisposition is just
of investigations involve collection of large family one piece of a complex puzzle, it is unlikely that so-
pedigrees, which are studied to determine inheri- ciety will move toward widespread genotyping for
tance of the trait or disorder. This method works early identification of individuals who are at risk
well when a single gene is responsible for the out- for tobacco use. Perhaps a more likely use of ge-
come; however, it becomes more difficult when netics as related to tobacco use is its potential for
multiple genes have an impact, such as with to- improving our treatment for dependence [91]. If
bacco use. In linkage studies of smoking, it is com- genetic research leads to new knowledge regarding
mon for investigators to identify families, ideally the mechanisms underlying the development and
with two or more biologically-related relatives that maintenance of dependence, it is possible that new,
have the trait or disorder under study (referred to more effective medications might be created. Fur-
as affected individuals, in this case, smokers) and thermore, through pharmacogenomics research we
other unaffected relatives. For example, data from might gain improved knowledge as to which pa-
affected sibling pairs with parents is a common de- tients, based on their genetic profiles, would be best
sign in linkage analysis. A tissue sample (typically treated with which medications. Researchers are be-
blood) is taken from each individual, and the sample ginning to examine how DNA variants affect health
undergoes genotyping to obtain information about outcome with pharmacologic treatments, with a
the study participant’s unique genetic code. If a goal of determining which genetic profiles respond
gene in a specific region of a chromosome is as- most favorably to specific pharmaceutical aids for
sociated with smoking, and if a genetic marker is cessation (e.g. [98,100–103]).
linked (i.e., in proximity), then the affected pairs
(such as affected sibling pairs) will have increased
odds for sharing the same paternal/maternal gene Benefits of quitting
[91].
As genetic research moves forward, new clues The reports of the US Surgeon General on the
provide insight into which genes might be promis- health consequences of smoking, released in 1990
ing “candidates” as contributors to tobacco use and and 2004, summarize abundant and significant
dependence. Currently, there are two general lines health benefits associated with giving up tobacco
of research related to candidate genes for smoking. [9,104]. Benefits noticed shortly after quitting (e.g.,
One examines genes that affect nicotine pharmaco- within 2 weeks to 3 months), include improvements
dynamics (the way that nicotine affects the body) in pulmonary function and circulation. Within
and the other examines genes that affect nicotine 1–9 months of quitting, the ciliary function of
pharmacokinetics (the way that the body affects the lung epithelium is restored. Initially, patients
nicotine). A long list of candidate genes are being might experience increased coughing as the lungs
examined—some of the most extensively explored clear excess mucus and tobacco smoke particu-
involve (a) the dopamine reward pathway (e.g., lates. In several months, smoking cessation results
those related to dopamine synthesis, receptor acti- in measurable improvements of lung function. Over
vation, reuptake, and metabolism) and (b) nicotine time, patients experience decreased coughing, sinus
20. Smoking Cessation 9
congestion, fatigue, shortness of breath, and risk for positive influence on survival rates. Although many
pulmonary infection and 1 year postcessation, the smoking cessation interventions are aimed at pri-
excess risk for coronary heart disease is reduced to mary prevention of cancer, these results indicate
half that of continuing smokers. After 5–15 years, that there can be substantial medical benefits for
the risk for stroke is reduced to a rate similar to individuals who quit smoking after they are diag-
that of people who are lifetime nonsmokers, and nosed with cancer.
10 years after quitting, an individual’s chance of
dying of lung cancer is approximately half that of Smoking cessation interventions
continuing smokers. Additionally, the risk of devel-
oping mouth, larynx, pharynx, esophagus, bladder, Effective and timely administration of smoking ces-
kidney, or pancreatic cancer is decreased. Finally, sation interventions can significantly reduce the risk
15 years after quitting, a risk for coronary heart dis- of smoking-related disease [110]. Recognizing the
ease is reduced to a rate similar of that of people who complexity of tobacco use is a necessary first step
have never smoked. Smoking cessation can also lead in developing effective interventions and trials for
to a significant reduction in the cumulative risk for cessation and prevention. The biobehavioral model
death from lung cancer, for males and females. of nicotine addiction and tobacco-related cancers
Smokers who are able to quit by age 35 can be presents the complex interplay of social, psycho-
expected to live an additional 6–9 years compared logical, and biological factors that influence tobacco
to those who continue to smoke [105]. Ossip-Klein use and addiction (Figure 1.1). These factors in turn
et al. [106] recently named tobacco use a “geriatric mediate dependence, cessation, and relapse in most
health issue.” Indeed, a considerable proportion of individuals, and treatment has been developed to
tobacco users continue to smoke well into their 70s address many of the factors noted in the model [38].
and 80s, despite the widespread knowledge of the
tobacco health hazards. Elderly smokers frequently The health care provider’s role
claim that the “damage is done,” and it is “too late and responsibility
to quit;” however, a considerable body of evidence Health care providers are uniquely positioned to
refutes these statements. Even individuals who assist patients with quitting, having both access to
postpone quitting until age 65 can incur up to four quitting aids and commanding a level of respect that
additional years of life, compared with those who renders them particularly influential in advising pa-
continued to smoke [24,106]. Therefore, elderly tients on health-related issues. To date, physicians
smokers should not be ignored as a potential target have received the greatest attention in the scien-
for cessation efforts. Health care providers ought to tific community as providers of tobacco cessation
remember that it is never too late to advise their treatment. Although less attention has been paid to
elderly patients to quit and to incur health benefits. other health care providers such as pharmacists and
A growing body of evidence indicates that con- nurses, they too are in a unique position to serve
tinued smoking after a diagnosis of cancer has the public and situated to initiate behavior change
substantial adverse effects. For example, these among patients or complement the efforts of other
studies indicate that smoking reduces the over- providers [64,111].
all effectiveness of treatment, while causing com- Fiore and associates conducted a meta-analysis
plications with healing as well as exacerbating of 29 investigations in which they estimated that
treatment side effects, increases risk of developing compared with smokers who do not receive an in-
second primary malignancy, and decreases over- tervention from a clinician, patients who receive
all survival rates [36–38,107–109]. On the other a tobacco cessation intervention from a physician
hand, the medical, health, and psychosocial bene- clinician or a nonphysician clinician are 2.2 and
fits of smoking cessation among cancer patients are 1.7 times as likely to quit smoking at 5 or more
promising. Gritz et al. [37] indicated that stopping months postcessation, respectively [112]. Although
smoking prior to diagnosis and treatment can have a brief advice from a clinician has been shown to
21. 10 Chapter 1
Social factors
• Culture
• Socio-economic status
• Media/peer/family influences
• Politics
Psychological factors
• Comorbidity Tobacco use,
• Personality Behavioral, Dependence,
Cancer
• Stress Neurochemical, Cessation, Relapse
Physiological factors
Biological factors
• Genetics
• Nutrition
Figure 1.1 Biobehavioral model of nicotine addiction and tobacco-related cancers. (Adapted from [38].)
lead to increased likelihood of quitting, more in- from self-help materials to individual cognitive–
tensive counseling leads to more dramatic increases behavioral therapy, enable individuals to more ef-
in quit rates [112]. Because the use of pharma- fectively recognize high-risk smoking situations, de-
cotherapy agents approximately doubles the odds velop alternative coping strategies, manage stress,
of quitting [7,112], smoking cessation interventions improve problem-solving skills, and increase social
should consider combining pharmacotherapy with support [113]. The Clinical Practice Guideline out-
behavioral counseling. lines a five-step framework that clinicians can apply
To assist clinicians and other health care providers when assisting patients with quitting. Health care
in providing cessation treatment, the US Public providers should: (a) systematically identify all to-
Health Service has produced a Clinical Practice Guide- bacco users, (b) strongly advise all tobacco users to
line for the Treatment of Tobacco Use and Dependence quit, (c) assess readiness to make a quit attempt, (d)
[112]. The Guideline is based on a systematic re- assist patients in quitting, and (e) arrange follow-up
view and analysis of scientific literature which yields contact. The steps have been described as the 5 A’s:
a series of recommendations and strategies to as- Ask, Advise, Assess, Assist, and Arrange follow-up
sist health care providers in delivering smoking (Table 1.3). Due to the possibility of relapse, health
cessation treatment. The Guideline emphasizes the care providers should also provide patients with
importance of systematic identification of tobacco brief relapse prevention treatment. Relapse preven-
users by health care workers and offering at least tion reinforces the patient’s decision to quit, reviews
brief treatment interventions to every patient who the benefits of quitting, and assists the patient in re-
uses tobacco. Among the most effective approaches solving any problems arising from quitting [112].
for quitting are behavioral counseling and pharma- The outlined strategy has been termed the 5 R’s
cotherapy, used alone or, preferably, in combination (Table 1.3): Relevance, Risks, Rewards, Roadblocks,
[112]. and Repetition. In the absence of time or expertise
for providing more comprehensive counseling, clin-
Behavioral counseling icians are advised to (at a minimum), ask about to-
Behavioral interventions play an integral role in bacco use, advise tobacco users to quit, and refer
smoking cessation treatment, either alone or in con- these patients to other resources for quitting, such
junction with pharmacotherapy. These interven- as a toll-free tobacco cessation quitline (1-800-QUIT
tions, which include a variety of methods ranging NOW, in the US).
22. Smoking Cessation 11
Table 1.3 The 5 A’s and 5 R’s for smoking cessation interventions.
5 A’s Ask about tobacco use Identify and document tobacco use status for every patient at every visit
Advise to quit Urge every tobacco user to quit in a clear, strong, and personalized manner
Assess readiness to make a Assess whether or not the tobacco user is ready to make a quit attempt in
quit attempt the next 30 days
Assist in quit attempt Use counseling and/or pharmacotherapy with the patient willing to make a
quit attempt to help him or her quit
Arrange follow-up Schedule follow-up contact, preferably within the first week after the quit
date
5 R’s Relevance Encourage the patient to indicate why quitting is personally relevant,
being specific as possible
Risk Ask the patient to identify the negative consequences of tobacco use,
including acute risks (e.g., short breath), long-term risks (e.g., cancer, and
environmental risks, e.g., cancer among family)
Rewards Request that the patient identify potential benefits of stopping tobacco
use (e.g., improved health)
Roadblocks Ask the patient to identify barriers or impediments to quitting and note
the elements of treatment that could address such barriers (e.g.,
withdrawal symptoms, fear of failure, lack of support)
Repetition Repeat the motivational intervention every time an unmotivated patient
visits the clinic setting
Adapted from [112].
Pharmaceutical aids for nicotine oral inhaler), sustained-release bupropion,
smoking cessation and varenicline tartrate. These are described in brief
below, and summaries of the prescribing informa-
According to the Clinical Practice Guideline [112], tion for each medication are provided in Table 1.4.
all patients attempting to quit should be encour-
aged to use one or more effective pharmacother- Nicotine replacement therapy
apy agents for cessation except in the presence of In clinical trials, patients who use NRT products are
special circumstances. These recommendations are 1.77 times as likely to quit smoking than are those
supported by the results of more than 100 controlled who receive placebo [7]. The main mechanism of
trials demonstrating that patients receiving pharma- action of NRT products is thought to be a stimula-
cotherapy are approximately twice as likely to re- tion of nicotine receptors in the ventral tegmental
main abstinent long-term (greater than 5 mo) when area of the brain, which results in dopamine release
compared to patients receiving placebo (Figure 1.2). in the nucleus accumbens. The use of NRT is to re-
Although one would argue that pharmacotherapy duce the physical withdrawal symptoms and to al-
is costly and might not be a necessary component leviate the physiologic symptoms of withdrawal, so
of a treatment plan for each patient, it is the most the smoker can focus on the behavioral and psy-
effective known method for maximizing the odds chological aspects of quitting before fully abstaining
of success for any given quit attempt, particularly nicotine. Key advantages of NRT are that patients
when combined with behavioral counseling [112]. are not exposed to the carcinogens and other toxic
Currently, seven marketed agents have an FDA- compounds found in tobacco and tobacco smoke,
approved indication for smoking cessation in the and NRT provides slower onset of action than nico-
US: five nicotine replacement therapy (NRT) for- tine delivered via cigarettes, thereby eliminating the
mulations (nicotine gum, nicotine lozenge, trans- near-immediate reinforcing effects of nicotine ob-
dermal nicotine patches, nicotine nasal spray, and tained through smoking (Figure 1.3). NRT products
23. 12
Table 1.4 FDA-approved medications for smoking cessation.
Nicotine replacement therapy (NRT) formulations
Bupropion SR Varenicline
Chapter 1
Gum Lozenge Transdermal preparations1 Nasal spray Oral inhaler
2 2 2 3 3 2
Nicorette , Generic Commit , Generic Nicoderm CQ Generic Patch Nicotrol NS Nicotrol inhaler Zyban , Generic Chantix3
OTC OTC OTC OTC/Rx Rx Rx Rx Rx
2 mg, 4 mg; 2 mg, 4 mg 24-hour release (formerly Habitrol) Metered spray 10 mg cartridge 150 mg sustained-release 0.5 mg, 1 mg tablet
original, FreshMint2, Fruit Chill2, mint 7 mg, 14 mg, 21 mg 24-hour release 0.5 mg nicotine in 50 L delivers 4 mg inhaled tablet
Product
mint, orange2 7 mg, 14 m g, 21 mg aqueous nicotine solution nicotine vapor
≥25 cigarettes/day: 4 mg 1st cigarette ≤30 minutes after >10 cigarettes/day : >10 cigarettes/day: 1–2 doses/hour 6–16 cartridges/day; 150 mg po q AM × 3 days, Days 1–3:
<25 cigarettes/day: 2 mg waking: 4 mg 21 mg/day × 6 weeks 21 mg/day × 4 weeks (8–40 doses/day) individualized dosing then increase to 150 mg 0.5 mg po q AM
1st cigarette >30 minutes after 14 mg/day × 2 weeks 14 mg/day × 2 weeks One dose = 2 sprays (one in pobid Days 4 –7:
Week 1–6: waking: 2 mg 7 mg/day × 2 weeks 7 mg/day × 2 weeks each nostril); each spray • Initially, use at least 0.5 mg po bid
1 piece q 1–2 hours delivers 0.5 mg of nicotine to 6 cartridges/day • Do not exceed 300 mg/day Weeks 2–12:
Week 7–9: Week 1–6: ≤10 cigarettes/day: ≤10 cigarettes/day: the nasal mucosa 1 mg po bid
• Best effects with • Treatment should be
1 piece q 2–4 hours 1 lozenge q 1–2 hours 14 mg/day × 6 weeks 14 mg/day × 6 weeks continuous puffing for initiated while patient is
Week 10–12: Week 7–9: 7 mg/day × 2 weeks 7 mg/day × 2 weeks • Maximum • Patients should begin
20 minutes still smoking
1 piece q 4–8 hours 1 lozenge q 2–4 hours – 5 doses/hour therapy 1 week prior to
Week 10–12: • Nicotine in cartridge is • Set quit date 1–2 weeks quit date
• May wear patch for 16 hours • May wear patch for 16 – 40 doses/day depleted after 20 minutes after initiation of therapy
• Maximum, 24 pieces/day 1 lozenge q 4–8 hours • Take dose after eating
if patient experiences hours if patient • For best results, initially use of active puffing Allow at least 8 hours
• Chew each piece slowly sleep disturbances experiences sleep at least 8 doses/day
• with a full glass of water
• Maximum, 20 lozenges/day • Patient should inhale into between doses
• Park between cheek and (remove at bedtime) disturbances Patients should not sniff, • Dose tapering is not
• Allow to dissolve slowly • back of throat or puff in • Avoid bedtime dosing to
gum when peppery or (remove at bedtime) swallow, or inhale through necessary
(20–30 min) • Duration: 8–10 weeks short breaths minimize insomnia
tingling sensation appears Nausea and insomnia are
Dosing
the nose as the spray is • Do not inhale into the •
(~15–30 chews) • Nicotine release may cause • Duration: 8 weeks being administered • Dose tapering is not side effects that are
a warm, tingling sensation lungs (like a cigarette) but necessary
• Resume chewing when taste Duration: 3 –6 mo usually temporary
• “puff’’ as if lighting a pipe
or tingle fades • Do not chew or swallow • Can be used safely with • Duration: 12 weeks; an
• Open cartridge retains NRT
• Repeat chew/park steps until • Occasionally rotate to additional 12 week course
potency for 24 hours
most of the nicotine is gone different areas of the mouth • Duration: 7–12 weeks, may be used in selected
(taste or tingle does not • Duration: up to 6 months with maintenance up to patients
• No food or beverages 15
return; generally 30 min) minutes before or during use 6 months in selected
• Park in different areas of Duration: up to 12 weeks patients
•
mouth
• No food or beverages 15 min
before or during use
• Duration: up to 12 weeks
• Mouth/jaw soreness • Nausea • Local skin reactions (erythema, pruritus, burning) • Nasal and/or throat irritation • Mouth and/or throat • Insomnia • Nausea
• Hiccups • Hiccups • Headache (hot, peppery, or burning irritation • Dry mouth • Sleep disturbances
• Dyspepsia • Cough • Sleep disturbances (insomnia) or abnormal/vivid sensation) • Unpleasant taste • Nervousness/difficulty (insomnia, abnormal
• Hypersalivation • Heartburn dreams (associated with nocturnal nicotine • Rhinitis • Cough concentrating dreams)
• Effects associated with • Headache absorption) • Tearing • Rhinitis • Rash • Constipation
incorrect chewing • Flatulence • Sneezing • Dyspepsia • Constipation • Flatulence
technique: • Insomnia • Cough • Hiccups • Seizures (risk is 1/1000 • Vomiting
Adverse effects
Lightheadedness • Headache • Headache [0.1%])
Nausea/vomiting
Throat and mouth
irritation